Track market-moving stories before they get noisy

Philadelphia, Pennsylvania--(Newsfile Corp. - July 30, 2026) - National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against Badger Meter, Inc. (NYSE: BMI) ("Badger Meter" or the "Company") on behalf of investors who purchased or acquired Badger Meter common stock during the period from April 18, 2024 through April 16, 2026 (the "Class Period").

Investor Deadline: Investors who purchased or acquired Badger Meter common stock during the Class Period may, no later than August 3, 2026, seek to be appointed as a lead plaintiff representative of the class. To learn your rights, CLICK HERE.

Milwaukee, Wis.-based Badger Meter provides flow measurement, water quality monitoring, and control solutions to water utilities, municipalities, and industrial customers across the world.

The complaint alleges that Defendants failed to disclose that: (i) Badger Meter's reported financial results during the Class Period were at least partially the product of pulling forward customer orders to recognize revenue early, rather than the organic demand growth they described; and (ii) this revenue-acceleration practice was masking deteriorating near-term order trends and consuming revenue that would otherwise have supported future periods.

On July 22, 2025, Badger Meter's second-quarter 2025 results fell below consensus estimates, with decelerating revenue growth and narrowing margins. Management guided to a sequential sales decline in the third quarter of 2025 while dismissing the weakness as ordinary business variability. On this news, shares dropped 16.5%, falling $40.42 per share to close at $204.80 per share on July 22, 2025.

On January 28, 2026, Badger Meter's fourth-quarter 2025 results again disappointed, with revenues missing expectations and utility water sales posting a 6% sequential decline. Management attributed the shortfall to project pacing dynamics it claimed had been previously communicated. On this news, shares fell approximately 11%, dropping $18.09 per share to close at $146.32 per share.

On April 17, 2026, Badger Meter disclosed first-quarter 2026 results reflecting significant year-over-year deterioration across all key metrics. Management newly attributed part of the weakness to softer short-cycle municipal demand and revealed that such demand variability existed throughout 2023 to 2025 but had gone undetected in reported results due to elevated backlog and active project work. On this news, shares fell more than 24%, declining $36.75 per share to close at $115.54 per share.

If you are a Badger Meter investor and would like to learn more about this action, CLICK HERE or please contact Berger Montague: Andrew Abramowitz at [email protected] or (215) 875-3015, or Caitlin Adorni at [email protected] or (267) 764-4865.

About Berger Montague
Berger Montague is one of the nation's preeminent law firms focusing on complex civil litigation, class actions, and mass torts in federal and state courts throughout the United States. With more than $2.4 billion in 2025 post-trial judgments alone, the Firm is a leader in the fields of complex litigation, antitrust, consumer protection, defective products, environmental law, employment law, securities, and whistleblower cases, among many other practice areas. For over 55 years, Berger Montague has played leading roles in precedent-setting cases and has recovered over $50 billion for its clients and the classes they have represented. Berger Montague is headquartered in Philadelphia and has offices in Chicago; Malvern, PA; Minneapolis; San Diego; San Francisco; Toronto, Canada; Washington, D.C., and Wilmington, DE.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/307236

Source: Berger Montague

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

The market expects Planet Fitness (PLNT - Free Report) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended June 2026. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.

The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on August 6. On the other hand, if they miss, the stock may move lower.

While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise.

Zacks Consensus EstimateThis fitness center operator is expected to post quarterly earnings of $0.85 per share in its upcoming report, which represents a year-over-year change of -1.2%.

Revenues are expected to be $355.96 million, up 4.4% from the year-ago quarter.

Estimate Revisions TrendThe consensus EPS estimate for the quarter has been revised 2.52% lower over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.

Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change.

Price, Consensus and EPS Surprise

Earnings WhisperEstimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. Our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction) -- has this insight at its core.

The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.

Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.

A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.

Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).

How Have the Numbers Shaped Up for Planet Fitness?For Planet Fitness, the Most Accurate Estimate is higher than the Zacks Consensus Estimate, suggesting that analysts have recently become bullish on the company's earnings prospects. This has resulted in an Earnings ESP of +3.37%.

On the other hand, the stock currently carries a Zacks Rank of #4.

So, this combination makes it difficult to conclusively predict that Planet Fitness will beat the consensus EPS estimate.

Does Earnings Surprise History Hold Any Clue?Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.

For the last reported quarter, it was expected that Planet Fitness would post earnings of $0.63 per share when it actually produced earnings of $0.74, delivering a surprise of +17.46%.

Over the last four quarters, the company has beaten consensus EPS estimates four times.

Bottom LineAn earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.

That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.

Planet Fitness doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.

An Industry Player's Expected ResultsAnother stock from the Zacks Leisure and Recreation Services industry, Lindblad Expeditions (LIND - Free Report) , is soon expected to post loss of $0.1 per share for the quarter ended June 2026. This estimate indicates a year-over-year change of +44.4%. Revenues for the quarter are expected to be $185.12 million, up 10.2% from the year-ago quarter.

Over the last 30 days, the consensus EPS estimate for Lindblad Expeditions has been revised 10.5% up to the current level. Nevertheless, the company now has an Earnings ESP of -14.93%, reflecting a lower Most Accurate Estimate.

When combined with a Zacks Rank of #2 (Buy), this Earnings ESP makes it difficult to conclusively predict that Lindblad Expeditions will beat the consensus EPS estimate. Over the last four quarters, the company surpassed consensus EPS estimates three times.

Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.

Omnicell (OMCL - Free Report) came out with quarterly earnings of $0.94 per share, beating the Zacks Consensus Estimate of $0.48 per share. This compares to earnings of $0.45 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +95.83%. A quarter ago, it was expected that this Omnicell Inc. would post earnings of $0.33 per share when it actually produced earnings of $0.55, delivering a surprise of +66.67%.

Over the last four quarters, the company has surpassed consensus EPS estimates three times.

Omnicell, which belongs to the Zacks Medical Info Systems industry, posted revenues of $312.21 million for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 0.83%. This compares to year-ago revenues of $290.56 million. The company has topped consensus revenue estimates four times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Omnicell shares have lost about 8.6% since the beginning of the year versus the S&P 500's gain of 6.9%.

What's Next for Omnicell?While Omnicell has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Omnicell was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.47 on $312.99 million in revenues for the coming quarter and $1.97 on $1.24 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical Info Systems is currently in the top 30% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

One other stock from the same industry, Senseonics Holdings (SENS - Free Report) , is yet to report results for the quarter ended June 2026. The results are expected to be released on August 6.

This medical technology company is expected to post quarterly loss of $0.55 per share in its upcoming report, which represents a year-over-year change of -37.5%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

Senseonics Holdings' revenues are expected to be $13.08 million, up 96.7% from the year-ago quarter.

New retail media network connects brands with Academy's high-value customers and delivers measurable performance across online and in-store sales

, /PRNewswire/ -- Academy Sports + Outdoors ("Academy") (Nasdaq: ASO), a leading full-line sporting goods and outdoor recreation retailer, today launched Academy Retail Media (ARM) as the next evolution of its omnichannel growth and customer strategy. ARM brings together Academy's expanding physical and digital reach, differentiated customer relationships, and longstanding brand partnerships to create more relevant customer experiences and measurable growth opportunities for advertisers.

The launch comes as Academy continues to expand its store footprint, boost e-commerce, and enhance customer personalization capabilities. With more than 320 stores across 21 states and a growing base of 52 million verified customers, ARM gives brand partners a new way to translate Academy's customer relationships and geographic reach into purchase-based audience intelligence, omnichannel activation and closed-loop measurement.

"ARM is a natural extension of how Academy is growing our business and deepening relationships with customers and brand partners," said Chad Fox, Executive Vice President and Chief Customer Officer. "Our stores, digital platforms, and customer insights give us a distinct view of how active families and sports and outdoor enthusiasts shop. By bringing those strengths together, we can help brands engage customers more meaningfully, demonstrate the business impact of their investment, and create a better, more personalized Academy experience."

ARM enables brands to reach verified Academy customers across onsite, in-app, and offsite channels and connect media exposure to online and in-store sales. Advertisers receive transparent, closed-loop measurement of same-SKU sales, broader brand halo and incremental lift, helping them optimize campaigns against outcomes such as return on advertising spend, customer acquisition, new product launches, reactivation and sales growth. For Academy customers, ARM will support more relevant product discovery, brand experiences, and offers throughout the shopping journey.

Academy's audiences include Always Game Families – active households with children in sports that purchase across eight or more categories and spend approximately twice as much annually as the average sporting goods and outdoor consumer – along with sporting families and outdoor enthusiasts. Several leading national brands are already activating ARM campaigns across awareness, consideration, and conversion, demonstrating early momentum as the network launches.

To learn more about ARM visit here.

About Academy Sports + Outdoors

Academy is a leading full-line sporting goods and outdoor recreation retailer in the United States. Originally founded in 1938 as a family business in Texas, Academy has grown to more than 300 stores across 21 states and counting. Academy's mission is to provide "Fun for All" and Academy fulfills this mission with a localized merchandising strategy and value proposition that strongly connects with a broad range of consumers. Academy's product assortment focuses on key categories of outdoor, apparel, sports & recreation and footwear through both leading national brands and a portfolio of private label brands. For more information, visit www.academy.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements include, among other things, statements regarding the anticipated benefits, capabilities and opportunities associated with Academy Retail Media. Actual results may differ materially from these expectations due to a variety of factors, including those set forth in Academy's filings with the U.S. Securities and Exchange Commission. Any forward-looking statement in this press release speaks only as of the date of this release. Academy undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments, or otherwise, except as may be required by law.

Media inquiries:
Meredith Klein, Vice President of Communications
346.826.6615
[email protected] 

Investor inquiries:
Dan Aldridge, Vice President of Investor Relations
832.739.4102
[email protected] 

SOURCE Academy Sports + Outdoors

Palomar’s High-Risk Insurance Strategy Is Paying Off BigRalph Lauren NYSE: RL said its stockholders elected all board nominees, ratified Ernst & Young LLP as its independent auditor for fiscal 2027 and approved the company’s executive-compensation program on an advisory basis at its 2026 annual meeting.

Executive Chairman Ralph Lauren opened the virtual meeting by highlighting what he described as the company’s strong performance during the year. Chief Legal Officer and Secretary Avery Fischer said stockholders representing more than one-third of outstanding voting shares were present online or by proxy, satisfying the company’s quorum requirement.

Get Ralph Lauren alerts:

Apparel Earnings Winners and Losers: Ralph Lauren Takes OffStockholders elected Angela Ahrendts, Linda Findley and Darren Walker as Class A directors. Holders of Class B shares elected Frank A. Bennack Jr., Cesar Conde, Debra Cupp, Michael George, Valerie Jarrett, Ralph Lauren, David Lauren, Patrice Louvet and Wei Zhang. Fischer said the Class A nominees received a plurality of votes cast, while all outstanding Class B shares voted in favor of the Class B nominees.

The company said Ernst & Young’s appointment as independent registered public accounting firm for the fiscal year ending April 3, 2027, was ratified by a majority vote. Stockholders also approved, on an advisory basis, the compensation of named executive officers and the company’s compensation philosophy, policies and practices.

Revenue Tops $8 Billion MarketBeat Week in Review – 04/13 - 04/17 President and CEO Patrice Louvet said the company’s first year under its “Next Great Chapter: Drive” strategic plan produced results above expectations. He said full-year reported revenue surpassed $8 billion for the first time, supported by retail and wholesale growth in every region.

Louvet said operating margin also exceeded expectations, as gross-margin expansion more than offset what he called the meaningful impact of tariffs. The company used cost savings to support investments in strategic priorities, including brand activations, artificial-intelligence capabilities and key-city ecosystems, he said.

“Both our top and bottom-line results exceeded expectations, supported by our diversified drivers of growth and our strongest quality of sales to date,” Louvet said.

Looking toward fiscal 2027, Louvet acknowledged a dynamic global operating environment but said the company remains focused on growth opportunities across regions and channels. He cited the company’s brand, core product offerings, high-potential categories, geographic expansion, technology and analytics capabilities, talent and balance sheet as key supports for its strategy.

Strategic Priorities Louvet outlined three areas of focus under the Drive plan:

Elevating and energizing the lifestyle brand through consumer engagement, storytelling, data and analytics. Growing core iconic products, which he said represent about 70% of the business, while expanding higher-potential categories including outerwear, handbags and women’s apparel. Building consumer ecosystems in the company’s top 30 cities globally while preparing for longer-term growth in the next 20 cities. Louvet said Ralph Lauren is making investments in marketing, technology and talent intended to support profitable and sustainable growth. He added that management expects the company’s model of operational discipline and long-term investment to support further margin expansion over the remainder of the strategic plan and beyond.

Stock Split Question In response to a stockholder question about a potential stock split, company representative Justin Picicci said Ralph Lauren regularly reviews its capital structure and allocation priorities, including potential actions such as a split. However, he said the company had no announcement to make at the meeting.

Fischer said final voting results will be reported in a Form 8-K filing within four business days of the annual meeting.

About Ralph Lauren (NYSE:RL)Ralph Lauren Corporation NYSE: RL is a global designer, marketer and distributor of premium lifestyle products under the Ralph Lauren name and a portfolio of related brands. The company, founded by Ralph Lauren in 1967 and headquartered in New York City, has grown from a single line of men's neckties into a global lifestyle business that spans apparel, accessories and home goods.

Ralph Lauren's product assortment includes menswear, womenswear and childrenswear along with footwear, leather goods, eyewear, fragrances and home furnishings.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Should You Invest $1,000 in Ralph Lauren Right Now?Before you consider Ralph Lauren, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ralph Lauren wasn't on the list.

While Ralph Lauren currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

30.7.2026 16:45, RACE

Italský výrobce luxusních sportovních vozů Ferrari zveřejnil výsledky hospodaření za druhý kvartál roku 2026. Tržby společnosti meziročně vzrostly o 8,4 % na 1,94 mld. EUR a překonaly očekávání trhu. Zisk EBITDA se meziročně zvýšil o 6,5 % na 755 mil. EUR a rovněž překonal tržní očekávání. Společnost zároveň zvýšila celoroční výhled.

Výsledky společnosti Ferrari (RACE) za 2Q 2026   2Q 2026 Konsensus 2Q 2026 2Q 2025 Tržby (mld. EUR) 1,94 1,87 1,79 Čistý zisk (mld. EUR) 0,46 0,44 0,43 Zisk na akcii (EPS, EUR/akcie) 2,62 2,49 2,38 Výsledky Tržby společnosti vzrostly ve 2Q meziročně o 8,4 % na 1,94 mld. EUR a překonaly očekávání trhu ve výši 1,87 mld. EUR.

Tržby Ferrari ve 2Q dle segmentu (v mld. EUR) Segment Tržby Konsenzus Meziroční změna Auta a náhradní díly  1,63 1,56 +8,1 % Sponzorství a reklamy 
0,21 0,22 +2,0 % Ostatní výnosy 0,1 0,08 +31 % Zisk EBITDA dosáhl 755 mil. EUR a meziročně vzrostl o 6,5 %, čímž překonal tržní konsensus ve výši 735,9 mil. EUR. EBITDA marže činila 39 %, v souladu s očekáváním trhu.

Zisk EBIT vzrostl meziročně o 9,6 % na 605 mil. EUR a překonal očekávání analytiků ve výši 575,4 mil. EUR. EBIT marže se zvýšila z 30,9 % na 31,2 %, zatímco trh očekával 30,7 %.

Čistý zisk dosáhl 463 mil. EUR, což představuje meziroční růst o 8,9 %. Analytici očekávali 435,4 mil. EUR.

Zisk na akcii vzrostl z 2,38 EUR na 2,62 EUR a překonal tržní konsensus ve výši 2,49 EUR.

Dodávky vozů: Ferrari ve 2Q dodalo 3 366 vozů, zatímco analytici očekávali 3 426 vozů.

V regionu EMEA, který zahrnuje Evropu, Střední východ a Afriku, dodávky meziročně vzrostly o 13 % na 1 856 vozů a překonaly očekávání trhu ve výši 1 574 vozů. V Americe dodávky meziročně poklesly o 21 % na 787 vozů, zatímco analytici očekávali přibližně 993 vozů. V pevninské Číně, Hongkongu a na Tchaj-wanu se dodávky meziročně snížily o 32 % na 185 vozů při očekávání 258 vozů. Ve zbytku asijsko-pacifického regionu dodávky poklesly o 7,4 % na 538 vozů, zatímco trh očekával přibližně 583 vozů. Roční výhled Ferrari zvýšilo výhled pro rok 2026 a nově očekává:

Tržby přibližně 7,6 mld. EUR, dříve přibližně 7,5 mld. EUR, při očekávání analytiků ve výši 7,57 mld. EUR; Očištěný zisk EBITDA alespoň 2,97 mld. EUR, dříve alespoň 2,93 mld. EUR, při očekávání analytiků ve výši 2,97 mld. EUR; Očištěný zisk EBIT alespoň 2,26 mld. EUR, dříve alespoň 2,22 mld. EUR, při očekávání analytiků ve výši 2,25 mld. EUR; Očištěný zisk na akcii alespoň 9,68 EUR, dříve alespoň 9,45 EUR, při očekávání analytiků ve výši 9,71 EUR; Průmyslové volné peněžní toky alespoň 1,55 mld. EUR, dříve alespoň 1,5 mld. EUR, při očekávání analytiků ve výši 1,53 mld. EUR. Zvýšení výhledu podle společnosti vychází z vyššího než původně očekávaného rozsahu personalizací vozů a nižších než předpokládaných negativních dopadů měnových kurzů po započtení zajištění.

Komentář CEO „Silné výsledky dosažené ve druhém čtvrtletí odrážejí naši disciplinovanou realizaci a pokračující sílu naší strategie. Přetrvávající trend v oblasti personalizace nám umožňuje zvýšit celoroční výhled,“ uvedl generální ředitel Ferrari Benedetto Vigna.

„Během jediného čtvrtletí jsme představili modely Ferrari Luce a Ferrari 12Cilindri Manuale: dva velmi odlišné sportovní vozy, které ztělesňují stejné DNA Ferrari a ukazují, jak jedinečným způsobem propojujeme tradici a inovace. V současnosti máme nejucelenější modelovou řadu v historii Ferrari a nadále zaznamenáváme zdravou poptávku, přičemž kniha objednávek plně pokrývá rok 2027,“ dodal Vigna.

Vývoj akcie Ferrari

Akcie Ferrari (RACE) přidávají 2,7 % na 396,29 USD Ukazatel   Ukazatel   Kapitalizace (mld. USD) 69,9 P/E 37,5 Vývoj za letošní rok (%) +7,2 Očekávané P/E 35,7 52týdenní minimum (USD) 312,5 Prům. cílová cena (USD) 436,9 52týdenní maximum (USD) 505,5 Dividendový výnos (%) 1,1
Zdroj: Bloomberg, Ferrari

Marek Krejčiřík, Fio banka, a.s.

Wall Street expects a year-over-year decline in earnings on lower revenues when 10x Genomics (TXG - Free Report) reports results for the quarter ended June 2026. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.

The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on August 6. On the other hand, if they miss, the stock may move lower.

While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise.

Zacks Consensus EstimateThis life science technology company is expected to post quarterly loss of $0.23 per share in its upcoming report, which represents a year-over-year change of -182.1%.

Revenues are expected to be $146.96 million, down 15% from the year-ago quarter.

Estimate Revisions TrendThe consensus EPS estimate for the quarter has been revised 1.73% higher over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.

Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts.

Price, Consensus and EPS Surprise

Earnings WhisperEstimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. Our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction) -- has this insight at its core.

The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.

Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.

A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.

Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).

How Have the Numbers Shaped Up for 10x Genomics?For 10x Genomics, the Most Accurate Estimate is higher than the Zacks Consensus Estimate, suggesting that analysts have recently become bullish on the company's earnings prospects. This has resulted in an Earnings ESP of +10.93%.

On the other hand, the stock currently carries a Zacks Rank of #3.

So, this combination indicates that 10x Genomics will most likely beat the consensus EPS estimate.

Does Earnings Surprise History Hold Any Clue?Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.

For the last reported quarter, it was expected that 10x Genomics would post a loss of$0.29 per share when it actually produced a loss of -$0.10, delivering a surprise of +65.52%.

Over the last four quarters, the company has beaten consensus EPS estimates four times.

Bottom LineAn earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.

That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.

10x Genomics appears a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.

Expected Results of an Industry PlayerCarlsmed, Inc. (CARL - Free Report) , another stock in the Zacks Medical Info Systems industry, is expected to report loss per share of $0.4 for the quarter ended June 2026. This estimate points to a year-over-year change of +72.8%. Revenues for the quarter are expected to be $18.52 million, up 53.3% from the year-ago quarter.

The consensus EPS estimate for Carlsmed, Inc. has remained unchanged over the last 30 days. However, a lower Most Accurate Estimate has resulted in an Earnings ESP of -18.99%.

When combined with a Zacks Rank of #3 (Hold), this Earnings ESP makes it difficult to conclusively predict that Carlsmed, Inc. will beat the consensus EPS estimate. The company beat consensus EPS estimates in each of the trailing four quarters.

Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.

Pagaya Technologies Ltd. (NASDAQ:PGY) shares are trading higher Thursday after the company reported second-quarter earnings.

Pagaya shares are climbing with conviction. Why is PGY stock up today? Pagaya Beats Estimates with Strong GrowthPagaya reported adjusted earnings per share of $1.07, beating the consensus estimate of 33 cents. In addition, it reported revenue of $365.63 million, beating the consensus estimate of $356.02 million.

Network volume reached a record $3.5 billion, up 33% year-over-year, driven by growth in the company’s Auto vertical. 

Fitch revised Pagaya’s corporate rating outlook to Positive, citing improvements in profitability, leverage, and interest coverage.

“Our record quarter reflects a flywheel that is clearly working: partners are sending more volume, adopting more products, and our network effects compound with every relationship we add,” said Gal Krubiner, CEO and Co-Founder of Pagaya.

Narrows FY GuidancePagaya sees third-quarter revenue of between $370.00 million and $390.00 million, versus the consensus estimate of $394.67 million. Furthermore, it narrowed its fiscal-year revenue guidance from between $1.40 billion and $1.57 billion to between $1.42 billion and $1.52 billion, versus the consensus estimate of $1.47 billion.

Pagaya Shares Race HigherPGY Price Action: At the time of publication, Pagaya shares are trading 11.18% higher at $18.00, according to data from Benzinga Pro.

This illustration was generated using artificial intelligence via Midjourney.

This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

EUR/JPY plunges on Thursday, down 2.54% on the day to trade around 182.60 at the time of writing, after a sudden surge in the Japanese Yen (JPY) triggered by what appears to be another intervention by Japanese authorities in the foreign exchange market. The move has been particularly violent, with the pair losing more than 400 pips in just a few minutes.

The JPY rally comes without any obvious economic catalyst, reinforcing speculation that the Japanese Ministry of Finance has stepped into the market to curb the currency's persistent weakness. USD/JPY is also tumbling below the 161.00 mark, while other major Japanese Yen crosses are posting broad-based losses.

The suspected intervention recalls the episode at the end of April, when the Japanese Yen appreciated by nearly 3% against the US Dollar after USD/JPY reached a high of 160.72. At that time, the Japanese Finance Minister Katayama Satsuki warned that "decisive" action was imminent, while top currency diplomat Atsushi Mimura described it as the market's "final warning." Two sources familiar with the matter later told Reuters that Japanese authorities had intervened to support the currency. Since then, the Finance Minister has continued to warn that further intervention remains possible as the Japanese Yen has continued to weaken.

Market attention now shifts to the Bank of Japan (BoJ) policy decision on Friday. The central bank is widely expected to leave its policy rate unchanged at 1%, but investors will closely watch the updated economic projections and Governor Kazuo Ueda's comments for clues on whether another rate hike could come as early as October or be delayed until December. A more hawkish message could extend the Japanese Yen's rebound and keep pressure on JPY crosses.

On the European side, the latest economic data has offered only limited support to the Euro (EUR). Preliminary figures showed that Germany's Gross Domestic Product (GDP) expanded by 0.2% QoQ in the second quarter, beating expectations of 0.1%, while annual growth accelerated to 0.9%.

Across the Eurozone, the economy expanded by 0.4% in the second quarter and 1% YoY, also exceeding market forecasts. Meanwhile, the European Commission reported an improvement in July Consumer Confidence and Economic Sentiment, although the Unemployment Rate edged up to 6.3%.

Japanese Yen Price Today The table below shows the percentage change of Japanese Yen (JPY) against listed major currencies today. Japanese Yen was the strongest against the US Dollar.

USDEURGBPJPYCADAUDNZDCHFUSD-0.56%-0.53%-2.58%-0.28%-0.91%-1.33%-1.12%EUR0.56%0.02%-2.00%0.34%-0.37%-0.79%-0.53%GBP0.53%-0.02%-2.01%0.30%-0.38%-0.79%-0.53%JPY2.58%2.00%2.01%2.37%1.73%1.29%1.57%CAD0.28%-0.34%-0.30%-2.37%-0.62%-1.05%-0.78%AUD0.91%0.37%0.38%-1.73%0.62%-0.41%-0.17%NZD1.33%0.79%0.79%-1.29%1.05%0.41%0.29%CHF1.12%0.53%0.53%-1.57%0.78%0.17%-0.29% The heat map shows percentage changes of major currencies against each other. The base currency is picked from the left column, while the quote currency is picked from the top row. For example, if you pick the Japanese Yen from the left column and move along the horizontal line to the US Dollar, the percentage change displayed in the box will represent JPY (base)/USD (quote).

Lantronix to develop a custom solution based on Lantronix’s Open-Q™ 6490CS SOM to support Swarmer’s AI software on small drones for defense missions, boosting onboard computing power by more than 400% compared to current platforms July 30, 2026 08:30 ET  | Source: Lantronix, Inc.

IRVINE, Calif., July 30, 2026 (GLOBE NEWSWIRE) -- Lantronix Inc. (Nasdaq: LTRX), a global provider of Edge AI and Industrial IoT solutions that power NDAA-compliant unmanned systems, critical infrastructure, and resilient enterprise networks, today announced a collaboration with Swarmer, Inc (Nasdaq: SWMR), a drone autonomy software company whose technology has supported more than 100,000 real-world combat missions in Ukraine since April 2024, to create a custom compute platform optimized for Group 1 UAS. Both companies are focused on accelerating deployment of FPV and other small, low-cost drones for Ukraine, U.S. and allied defense programs.

“Autonomy software only proves itself once it’s deployed on hardware that’s actually flying,” said Saleel Awsare, president and CEO of Lantronix. “A production-ready NDAA-compliant Lantronix compute platform with Swarmer’s combat-proven software provides operators with roughly four times the processing power to optimize its visual navigation, automated target recognition, pixel lock and advanced teaming algorithms.”

The integration of Lantronix's Open-Q™ 6490CS System-on-Module is designed to provide Group 1 UAS with the identical connectivity options along with a significant increase in onboard computing capability, enabling more advanced artificial intelligence, computer vision and autonomous mission execution at the tactical edge. The additional processing capacity will support more sophisticated swarming behaviors, sensor fusion and real-time decision-making while providing a production-ready platform designed for long-term deployment.

For military operators, this will result in the ability to field increasingly autonomous, software-defined Group 1 UAS that can adapt to evolving mission requirements through software updates rather than hardware replacement, extending operational capability while reducing lifecycle complexity.

“With more than seven million drones projected to be manufactured this year alone, we believe that every one of them could potentially run our AI and collaborative autonomy software,” said Alex Fink, president and U.S. CEO of Swarmer. “Our collaboration with Lantronix will produce a compute platform that is capable of running AI models on the edge in a small form factor that is optimized for Group 1 UAS. We believe this will become the new industry standard compute solution for small unmanned systems, and every unit will arrive pre-populated with Swarmer OS and Swarmer’s cutting-edge autonomy.”

Founded in Austin, Texas, in May 2023, Swarmer deployed its autonomy software in combat operations in Ukraine in April 2024 and has since flown missions with nearly 50 Ukrainian military units in active electronic warfare and GNSS-denied environments. Swarmer’s software is designed to run across any type of drone — from fixed-wing and rotary-wing aircraft to ground vehicles and sea vessels. The Swarmer solution based on Lantronix Open-Q™ 6490CS SOM will support all of these platforms, allowing a single operator to plan, monitor and execute missions involving hundreds of drones from one hardware base.

How Lantronix Technology Benefits Swarmer
The Open-Q™ 6490CS SOM enables Swarmer to deploy its autonomy software on a production-ready compute platform that improves performance, reduces cost and operational inefficiencies, optimizes SWaP and accelerates deployment across multiple unmanned platforms. On-device AI processing is built for GPS-denied and contested environments, where cloud-dependent compute isn’t reliable.

Sustained production support and NDAA compliance also eliminates supply chain uncertainty, enabling Swarmer to scale deployments across U.S. and allied government customers without hardware availability concerns.

Key Investor Takeaways

Expanded platform opportunity: Broadens Lantronix's role within autonomous defense systems by improving AI compute for multi-platform autonomy software across air, ground and maritime unmanned systems. 

Replaces Soon-to-be Obsolete Technology: Current onboard compute systems are becoming increasingly expensive and unable to match pace with the speed of AI. This customized platform is designed to provide roughly four times the processing power to optimize visual navigation, automated target recognition, pixel lock and advanced teaming algorithms. 

Long-term program support: NDAA compliance and a 10-year-plus production commitment position Lantronix for recurring, long-term revenue as Swarmer secures extended defense contracts, de-risking platform adoption in the defense autonomy market.

Validated, scaling partner: Swarmer (Nasdaq: SWMR) is a publicly traded, combat-proven operator with more than 100,000 missions flown across nearly 50 military units, reducing execution risk on the demand side of the partnership.

About Swarmer

Swarmer™ (Nasdaq: SWMR) is a defense technology company that specializes in vendor-agnostic software which allows one operator to intuitively control hundreds of autonomous platforms in real time. Swarmer’s primary mission areas include autonomous swarm coordination, integration of multi-domain unmanned systems and AI-powered autonomy software for distributed operations. Swarmer is not a drone manufacturer and does not depend on any single platform, supplier or hardware lifecycle. Instead, Swarmer operates at the intelligence layer, developing autonomy, coordination and decision-making software that enables large numbers of low-cost unmanned systems to operate collectively as one coherent, resilient force. Swarmer’s technology has been rigorously validated in real-world kinetic environments and was first deployed in combat operations in Ukraine in April 2024. Since then, it has completed more than 100,000 combat missions, generating terabytes of proprietary data that informs its machine-learning models and enables the replication of advanced pilot performance at scale. Swarmer’s routine use in combat missions generates continuous streams of telemetry, sensor data and operational feedback which are then used to refine performance, increase resilience and accelerate learning. Swarmer has headquarters in Austin, Texas, and maintains operations and teams in Ukraine, Poland and Estonia. For more information, visit www.getswarmer.com.

About Lantronix

Lantronix Inc. (Nasdaq: LTRX) is a global leader in Edge AI and Industrial IoT solutions, delivering intelligent computing, secure connectivity and remote management for mission-critical applications. Serving high-growth markets, including smart cities, enterprise IT and commercial and defense unmanned systems, including drones, Lantronix enables customers to optimize operations and accelerate digital transformation. Its comprehensive portfolio of hardware, software and services powers applications from secure video surveillance and intelligent utility infrastructure to resilient out-of-band network management. By bringing intelligence to the network edge, Lantronix helps organizations achieve efficiency, security and a competitive edge in today’s AI-driven world. For more information, visit the Lantronix website.

“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking statements within the meaning of federal securities laws, including, without limitation, statements concerning a potential collaboration between Lantronix and Swarmer and Lantronix’s positioning to capitalize on opportunities for long-term growth in the drone and defense technology markets. These forward-looking statements are based on our current expectations and are subject to substantial risks and uncertainties that could cause our actual results, future business, financial condition, or performance to differ materially from our historical results or those expressed or implied in any forward-looking statement contained in this news release. The potential risks and uncertainties include, but are not limited to, such factors as the effects of negative or worsening regional and worldwide economic conditions or market instability on our business, including effects on purchasing decisions by our customers; our ability to mitigate any disruption in our and our suppliers’ and vendors’ supply chains due to changes in U.S. or foreign government trade policies, including recently increased or future tariffs, a pandemic or other outbreaks, wars and recent conflicts in Europe, Asia and the Middle East, or other factors; future responses to and effects of public health crises; cybersecurity risks; changes in applicable U.S. and foreign government laws and regulations; the risk that no definitive agreement between Lantronix and Swarmer is reached; our ability to successfully implement our acquisitions strategy or integrate acquired companies; difficulties and costs of protecting patents and other proprietary rights; the level of our indebtedness, our ability to service our indebtedness and the restrictions in our debt agreements; and any additional factors included in our Annual Report on Form 10-K for the fiscal year ended June 30, 2025, filed with the Securities and Exchange Commission (the “SEC”) on Aug. 29, 2025, including in the section entitled “Risk Factors” in Item 1A of Part I of that report, as well as in our other public filings with the SEC. Additional risk factors may be identified from time to time in our future filings. In addition, actual results may differ as a result of additional risks and uncertainties about which we are currently unaware or which we do not currently view as material to our business. For these reasons, investors are cautioned not to place undue reliance on any forward-looking statements. The forward-looking statements we make speak only as of the date on which they are made. We expressly disclaim any intent or obligation to update any forward-looking statements after the date hereof to conform such statements to actual results or to changes in our opinions or expectations, except as required by applicable law or the rules of the Nasdaq Stock Market LLC. If we do update or correct any forward-looking statements, investors should not conclude that we will make additional updates or corrections.

©2026 Lantronix, Inc. All rights reserved. Lantronix is a registered trademark. Other trademarks and trade names are those of their respective owners.

Investor Contact (Lantronix):
Matt Glover and Greg Robles
Gateway Group, Inc.
[email protected]

Investor Contact (Swarmer):
[email protected] 

Media Contact (Lantronix):
Diana Puckett
[email protected]

Media Contact (Swarmer): 
[email protected] 

CNX Resources Corporation. (CNX - Free Report) came out with quarterly earnings of $0.72 per share, beating the Zacks Consensus Estimate of $0.57 per share. This compares to earnings of $0.59 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +26.32%. A quarter ago, it was expected that this company would post earnings of $0.93 per share when it actually produced earnings of $1.21, delivering a surprise of +30.11%.

Over the last four quarters, the company has surpassed consensus EPS estimates four times.

CNX Resources, which belongs to the Zacks Oil and Gas - Exploration and Production - United States industry, posted revenues of $389.44 million for the quarter ended June 2026, missing the Zacks Consensus Estimate by 5.66%. This compares to year-ago revenues of $450 million. The company has topped consensus revenue estimates three times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

CNX Resources shares have lost about 5.6% since the beginning of the year versus the S&P 500's gain of 6.9%.

What's Next for CNX Resources?While CNX Resources has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for CNX Resources was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.56 on $411.37 million in revenues for the coming quarter and $2.84 on $1.91 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Oil and Gas - Exploration and Production - United States is currently in the bottom 12% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

One other stock from the same industry, Riley Exploration Permian, Inc. (REPX - Free Report) , is yet to report results for the quarter ended June 2026. The results are expected to be released on August 5.

This company is expected to post quarterly earnings of $1.53 per share in its upcoming report, which represents a year-over-year change of +6.3%. The consensus EPS estimate for the quarter has been revised 6.6% lower over the last 30 days to the current level.

Riley Exploration Permian, Inc.'s revenues are expected to be $149.13 million, up 74.7% from the year-ago quarter.

Mark Zuckerberg has Meta investing heavily in AI. Bloomberg/Getty Images As tech giants aggressively build out compute to meet the demands of the AI boom, some face a tricky dilemma: how much should they hoard and how much should they sell?

Meta CEO Mark Zuckerberg addressed the issue on the company's Q2 earnings call this week. While Meta doesn't currently have a business selling compute — the data center processing power used to run AI — to customers, Zuckerberg has said it's on the cards.

Zuckerberg said that a "significant portion" of its compute will go toward training Meta's AI models, powering agents, and growing its core business. "But we also expect to grow a large business serving large customers as well," he said.

Tech giants are racing to build out more compute to power soaring demand for artificial intelligence. Google and Meta both just slightly raised their capex forecast for the year, and Google signaled 2027 will likely be even bigger (in a rare move, Microsoft held the line on its capex projections).

All that spending is now showing up in the financials: Google's cash flow went negative in Q2 for the first time in the company's history, and Meta's plunged 91% from the previous year.

Selling compute is one way to offset that cash problem, but it also comes with an opportunity cost. The common refrain from execs across the companies is that there simply isn't enough compute to go around. These companies are racing to stay ahead in the AI race, and employees sometimes compete for access to compute.

It's a conundrum for Microsoft, too. As Business Insider's Dan DeFrancesco put it earlier this week: "Does it cash in on demand today or focus more on its long-term goals?"

On Wednesday's earnings call, Microsoft CFO Amy Hood said that "customer demand continues to exceed available capacity" for its cloud business.

'Foolish' to take a short-term profitZuckerberg returned to this problem later in the call on Wednesday. "Obviously, a common trade-off that we need to make is around how much do you monetize something today versus develop future assets for the future?" he said.

"It would be foolish to basically just sell all of the compute and take a short-term profit," he said, adding that improved intelligence would compound the value of the compute.

Hoarding too much compute could also be bad for the lucrative cloud businesses of hyperscalers like Google. "If you don't have enough compute for enterprises, they'll go right back to Amazon or Microsoft," said Bernstein analyst Mark Shmulik in a research note on Google last week.

Last week, Google said it would buy more third-party compute to satisfy customer demand as it builds out more internal compute for itself.

Google CEO Sundar Pichai.  Raj K Raj/Hindustan Times via Getty Images Google is also building its own chips, known as tensor processing units, or TPUs, which it is putting into other data centers with partners to unlock more capacity.

"Our first priority is making sure we are allocating what we need to compete at the frontier in terms of AGI development," said CEO Sundar Pichai on last week's earnings call, referring to how Google is using TPUs. "That is the foundation for everything we do."

While Google leans on its cloud business to boost growth, it also needs to hold enough compute for itself to protect its moat around Search, Shmulik said in last week's note.

Oh, and it also needs to keep developers happy and locked into its ecosystem, which means allocating — you guessed it — more compute.

Microsoft CEO Satya Nadella Sven Hoppe/picture alliance via Getty Images Meta's message to investors: The AI spending will continue until returns improve.

Investors' response: No thanks.

AI spend was the big focus during Meta's Q2 earnings report. And the pitch wasn't convincing enough to stop an after-hours selloff.

Meta was happy to credit AI with helping its advertising business (its bread and butter) rise 27%. And it wasn't just pure growth. Ad impressions grew 14%, while the average price per ad climbed 12%.

There's just one catch. Meta is still spending an incredible amount — $31.1 billion, roughly double what it spent last year — on its AI bets. That's eating up a significant portion of its free cash flow, which went from $8.55 BILLION to $784 MILLION. One analyst said the AI strategy is like "throwing spaghetti at the wall."

Investors were unimpressed, with Meta's stock falling nearly 10% at one point after the bell.

Compare that to another tech giant that reported yesterday: Microsoft. It logged wins in Azure and Microsoft 365 Copilot, which Microsoft CFO Amy Hood touted in her quarterly memo to employees viewed by BI's Ashley Stewart. Perhaps more importantly, its AI budget forecast didn't budge.

Investors noticed. Microsoft's stock jumped almost 8% in after-hours trading.

The difference between the two is clear: AI spending is fine … as long as there is a direct and measurable return.

CEO Mark Zuckerberg made the case for why Meta's AI bets might need more time.

A lot of the most immediate use cases for AI are for developers. Just look at the boom in vibe coding. "Building for consumers is a little bit different," Zuckerberg said during Wednesday's earnings call, but it's also a "massive market opportunity."

And who better to serve that market than the king of all social networks? Between Facebook, Instagram, WhatsApp, and Threads, Meta has billions of users across its platforms. Zuckerberg said Meta's making a big bet on AI agents.

That all tracks with one small exception: A lot of Americans are really nervous about AI.

Meta has tried to ease those fears with a big AI PR push, including a Zuckerberg op-ed and some interviews with reporters. (The request to speak to BI Today must have got caught in my spam inbox. I'm happy to chat, Mark. Sounds like you have a really cool gym.)

BI's Peter Kafka has an idea about how Meta could better convince people to get on board with AI. (Hint: It's green.)

Whatever the plan is, Meta had better figure something out fast. Investors are running out of patience.

Dan DeFrancesco You're currently following this author! Want to unfollow? Unsubscribe via the link in your email.

Dan is the lead writer for BI Today, Business Insider's flagship daily newsletter. Dan often interviews executives about everything from AI's impact on capitalism to robotics to the potential SaaSpocalypse as part of his work on the newsletter.Dan was an editor and reporter at BI, covering financial technology and market structure.His previous work includes everything from inside Robinhood's failed "Checking and Savings" product that eventually led to Congress getting involved to the internal arguments over JPMorgan's failed attempt to launch a finance app for millennials.Before joining Business Insider, Dan wrote about risk management in derivatives markets for Risk.net and fintech for WatersTechnology. He initially covered local sports for The Journal News, a daily newspaper serving the lower Hudson Valley. Got a tip? Contact this editor via email at [email protected].

Newsletters Newsletter

Along with producing a 9.82% extended-session stock upsurge from $390.54 to $428.91, Microsoft’s (NASDAQ: MSFT) latest earnings report led to a veritable deluge of analyst rating and price target upgrades.

Furthermore, among more than a dozen notes, only one positioned MSFT shares as a ‘Hold.’ Still, even the comparatively bearish assessment by Stifel Nicolaus’ Brad Reback came with a stock price forecast lift from $400 to $450.

On the other end of the spectrum, Rishi Jaluria of RBC Capital assessed that Microsoft shares are headed toward $640 in the coming 12 months, while Bernstein’s Mark Moerdler dropped the old $646 price target in favor of the new $647.

Both of the bullish analysts also issued positive recommendations for MSFT stock, much like the vast majority of their peers.

Overall, and following the latest string of notes, Microsoft is considered a ‘Strong Buy’ on Wall Street and expected to rally 42.44% to $556.29 on average by analysts, per the data Finbold retrieved from TipRanks on July 30.

Wall Street sets Microsoft stock price target for the next 12 months. Source: TipRanks Why Microsoft stock is seen as a ‘Strong Buy’ on Wall Street Meanwhile, the Thursday morning positivity can be linked directly to the blue-chip technology giant’s latest earnings report. Specifically, Microsoft reported $90.01 billion in revenue and earnings per share (EPS) of $4.74.

Forecasts called for $4.24 EPS and $87.62 billion in sales, meaning the big tech company managed a double beat. 

Additionally, Azure cloud growth accelerated to 43% – faster than the predicted 40% – reinforcing the positivity, and investors appear to have remained unfazed concerning capital expenditures (CapEx), in stark contrast to Google’s (NASDAQ: GOOGL) filing made a week before and Meta’s (NASDAQ: META) presentation made public on Wednesday afternoon.

Investors react to latest Microsoft earnings report Indeed, after dropping 17.42% between January 2 – the first regular session of the year – and the closing bell on July 29, Microsoft stock suddenly soared 9.82% to its press time price of $428.91.

Microsoft stock price YTD chart. Source: TipRanks The move might present a turning point for the embattled technology giant, and it decreased the year-to-date (YTD) market capitalization loss to roughly $500 billion, down from $750 billion.

Featured image via Shutterstock

Best Crypto Exchange for Intermediate Traders and Investors

Invest in cryptocurrencies and 3,000+ other assets including stocks and precious metals.

0% commission on stocks - buy in bulk or just a fraction from as little as $10. Other fees apply. For more information, visit etoro.com/trading/fees.

Copy top-performing traders in real time, automatically.

eToro USA is registered with FINRA for securities trading.

30+ million Users worldwide

eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk. Don’t invest unless you’re prepared to lose all the money you invest. This is a high-risk investment and you should not expect to be protected if something goes wrong. Take 2 mins to learn more.

Join Finbold's newsroom, become a Sales Executive today! Apply now to join Finbold as a crypto/finance news writer!

AMD (NASDAQ:AMD | AMD Price Prediction) trades at $429.56 against an average Wall Street price target of $575.49, a gap of roughly 34% between current levels and consensus. Baird analyst Tristan Gerra recently pushed a target of $1,250, implying roughly 191% upside. That outlier reflects AMD’s emergence as the number-two AI accelerator franchise behind NVIDIA at a moment the market is repricing the group.

The disconnect matters because operating performance held firm. Q1 FY2026 revenue of $10.253 billion grew 37.85% year over year, non-GAAP EPS of $1.37 beat the $1.2939 consensus, and Data Center revenue jumped 57%. The tape tells a different story than the P&L.

A Violent Reset in a Stock That Just Beat AMD is down 20.38% over the past month and 22.23% in the past week. Measured from the June 30 close, shares have fallen 26.05%. That qualifies as violent for a large-cap semiconductor name that just guided Q2 revenue to approximately $11.2 billion, implying 46% year-over-year growth.

Catalysts trace to broader macro pressures. Broader tech sentiment has been pressured by renewed U.S.-Iran tensions, surging crude oil prices, and concerns about restrictive Federal Reserve policy, layered onto a narrative hitting AMD directly: fears that cheaper AI models could reduce demand for expensive AI infrastructure. JPMorgan CEO Jamie Dimon separately flagged potential credit risks from AI infrastructure financing, denting hyperscale capex sentiment.

Fundamentals held up cleanly. Non-GAAP gross margin expanded 170 basis points year over year to 55%, and free cash flow surged 252.96% to $2.566 billion. This looks like a valuation reset.

What Baird Sees at $1,250 The bull case has not softened. Consensus target of $575.49 still implies roughly 34% upside, and the rating profile of 42 Buys, 9 Holds, and zero Sells reflects reiterations rather than downgrades in recent weeks.

Gerra sits at the aggressive end with a multi-year full-stack capture thesis. He frames AMD’s server CPU and GPU total addressable market as expanding toward $220 billion-plus, and projects data center AI GPU revenue reaching roughly $147 billion by 2030 as AMD captures about 15% market share in enterprise and hyperscale AI accelerators.

Catalysts are MI450 accelerator platform and next-generation Venice EPYC architecture ramping into hyperscale deployments alongside Meta, OpenAI, and Microsoft. Lisa Su told investors on the Q1 call that Meta has committed to up to 6 gigawatts of AMD Instinct GPU deployment, OpenAI to another 6 GW, and Oracle Cloud is standing up a 50,000-GPU Helios supercluster. The $1,250 is a swing rather than a base case, but underlying commitments are real.

The AI Chip Cohort Did Not Sell Off Together AMD’s dislocation stands out. The rest of the AI accelerator complex barely moved.

NVIDIA (NASDAQ:NVDA) fell just 2.54% over the past month. At $190.01 versus an average target of $302.83, implied upside runs near 59%, on a rating stack of 58 Buys, 2 Holds, and 1 Sell. Recent revisions skewed higher after the Q1 FY27 report.

Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and AMD didn't make the cut. Grab the names FREE today.

Broadcom (NASDAQ:AVGO) is down only 0.57%. Shares at $370.32 against a $527.00 target imply roughly 42% upside, with 44 Buys and 4 Holds and estimates trending up after AI semiconductor revenue guided to $16.0 billion for Q3.

Intel (NASDAQ:INTC) fell harder than AMD, off 37.84% over the month. At $81.88 versus a $115.27 average target, implied upside is around 41%, but conviction is thinner: 32 Holds against 13 Buys and 4 Sell-side ratings.

On consensus, largest analyst-implied upside sits at NVIDIA. Excluding Baird’s outlier, AMD ranks below NVDA and roughly even with AVGO and INTC. Include Gerra’s $1,250 target and AMD’s ceiling towers over the entire cohort.

What the Tape Actually Says AMD trades at $429.56, with consensus target of $575.49 implying roughly 34% upside. Analyst posture across the 51-analyst coverage universe skews decisively bullish.

Buy ratings: 42 Hold ratings: 9 Sell ratings: 0 The stock is up 100.58% year to date and 142.09% over the past year, even after the recent drawdown. The S&P 500 is up 6.97% year to date and down 1.56% over the past month. AMD has demolished the index on the year and given a large chunk back in four weeks.

Where I Come Out on AMD Here The bull case holds if the Baird framework is directionally correct: MI450 and Venice EPYC convert announced Meta, OpenAI, and Oracle commitments into hyperscale revenue at the pace Su has signaled, and AMD holds mid-teens share of AI accelerators through the decade. That path leads back to the $575 consensus, with $1,250 sitting on top only if 2030 modeling proves right.

The bear case builds if the market correctly prices a demand ceiling on high-end AI infrastructure, or if China export controls on MI308 returns as a recurring drag. At 69x forward earnings, there is not much cushion for either.

My lean is modestly constructive. Q1 was too strong to read the 20% drawdown as fundamental, and peer tape shows selective damage across the cohort. The consensus $575 target looks defensible if August 4 earnings confirm trajectory. Baird’s $1,250 is a valid ceiling to note.

Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and AMD didn't make the cut. Grab the names FREE today.

Contact [email protected] for any questions or corrections.

Although Wall Street keeps rehearsing the dot-com script every time a semiconductor stock rips higher, Fox Business host Charles Payne argues on the Rich Habits Podcast that the comparison “wastes a lot of time” and “creates a lot of hesitation” for investors watching a generational buildout pass them by. The reflex is understandable. Cisco Systems (NASDAQ:CSCO | CSCO Price Prediction) was briefly the most valuable company on earth in March 2000, then collapsed roughly 89% by 2002, and the stock still has not recaptured that peak 26 years later. But the load-bearing question is not whether the chart looks similar. It is whether the earnings underneath match.

The Long Memory pattern Payne cites concerns the mechanism that caused the crash, not the crash itself. Cisco’s growth in the late 1990s came largely from acquisitions rather than organic expansion, and its customers were money-losing dot-coms burning venture capital that later imploded. That is what a bubble looks like from the inside: revenue growth that depends on other people’s speculation. What Payne asks investors to do is boring and useful. Check whether earnings per share are following the stock price higher. Check organic versus acquisition-driven growth. Check PE, forward PE, and PEG.

NVIDIA Broke the Mold Run that test on NVIDIA (NASDAQ:NVDA) and the parallel breaks. In its most recent quarter, filed May 20, NVIDIA posted revenue of $81.615 billion, up 85.23% year over year, non-GAAP EPS of $1.87 against a $1.77 estimate, and non-GAAP gross margin of 75.0%. Data Center revenue alone reached $75.246 billion, up 92% year over year, with networking up 199%. Net income climbed 210.63%. That is operating leverage, not acquisition accounting.

The valuation gut-check matters here. Cisco at its 2000 peak carried a price-to-earnings ratio in the 130x to 200x range with revenue growth in the 40s to 50s. NVIDIA today trades at a trailing P/E of 40 with 85% revenue growth and a return on equity of 101.49%. The tape looks like the dot-com era. The math does not. NVIDIA has beaten EPS estimates in every single quarter from FY2023 Q1 through FY2026 Q2, and the surprise magnitudes have compressed as analysts finally catch up to the run rate.

Payne’s second test is who is writing the checks. The customer base is where dot-com Cisco failed the audit. NVIDIA’s customers are the most profitable enterprises on the planet, and their AI revenue is contracted, not vaporware. Microsoft (NASDAQ:MSFT) told investors on its most recent call that its “AI business surpassed $37 billion ARR, up 123%”, with commercial remaining performance obligations, its committed backlog, at $627 billion. Microsoft added “another gigawatt of capacity this quarter” and is on track to double its footprint in just two years. Money that has already been signed for is not a bubble.

Don't wait: the analyst who called NVIDIA in 2010 just revealed his top 10 AI stocks. See the full list FREE now.

A Historical Comparison Payne’s deeper historical mirror is the 1860s, well before 1999. Between 1860 and the early 1900s, America eclipsed the rest of the world, life expectancy grew and disposable income appeared for the first time, largely on the back of the railroads and the second industrial revolution. That buildout also produced spectacular busts and forgotten winners. Payne concedes the point directly: “Not all the AI winners today may be relevant 10 years from now.” The pattern is that the platform survives even when specific tickers do not. What is different this time, in his framing, is access. In the railroad era “maybe there were 1,000 investors, period,” where today “everyone’s got an opportunity to get involved and to ride this wave.”

The Cisco cautionary tale still deserves respect. Even now, with Cisco riding a real AI networking cycle of its own, revenue of $15.8 billion up 12% year over year and a raised FY26 hyperscaler AI order outlook of roughly $9 billion, the stock has returned only 171.25% cumulatively since March 1, 2000. That is the ceiling a broken multiple can impose on a good business for a quarter century. Jensen Huang’s read on the current cycle is a different order of magnitude. He told analysts NVIDIA sees “$1 trillion in Blackwell and Rubin revenue” through calendar 2027 and forecasts AI infrastructure spending on track to reach $3 trillion to $4 trillion annually by the end of this decade.

The pattern that repeats is the buildout, well beyond the crash. Railroads, electrification, the internet, and now AI factories all produced periods where the stock market ran ahead of proof, then waited for earnings to catch the tape. Payne’s argument, tested against the numbers, is that NVIDIA’s earnings are pulling the tape higher rather than chasing it. Long term, Wall Street tends to sort platform winners from tourists on the strength of free cash flow, and $48.554 billion of quarterly free cash flow is the sort of receipt that Cisco in 2000 could not produce. The window Payne describes is open. The homework he demands is what keeps investors on the right side of it.

Don't wait: the analyst who called NVIDIA in 2010 just revealed his top 10 AI stocks. See the full list FREE now.

Contact [email protected] for any questions or corrections.

Priority Review reinforces the significant potential of subcutaneous amivantamab in recurrent or metastatic head and neck cancer, where the current five-year survival rate is only 15 percent  Patients achieved rapid, deep and durable responses, including a 42 percent overall response rate with one-third achieving a complete response  Subcutaneous amivantamab is the only therapy in head and neck cancer engineered to target both EGFR and MET, proven drivers of tumor growth and treatment resistance , /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to the supplemental Biologics License Application (sBLA) for subcutaneous amivantamab and hyaluronidase-lpuj for adults with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). If approved, it would provide a new treatment for patients whose disease has progressed following platinum-based chemotherapy and a PD-1 or PD-L1 inhibitor. Priority Review is granted to medicines that may offer significant improvements in safety or effectiveness for serious conditions and shortens the FDA review timeline to approximately six months.1

"One of the hardest things about advanced head and neck cancer is that it can impact our most basic functions, like the ability to speak, eat, and even breathe easily, profoundly affecting patients' daily lives. For those whose disease progresses despite prior treatment, that burden is compounded by limited treatment options and poor outcomes," said Yusri Elsayed, M.D., M.H.Sc., Ph.D., Global Therapeutic Area Head, Oncology, Johnson & Johnson. "Building on the established role of subcutaneous amivantamab in lung cancer, this milestone underscores its continued potential across multiple tumor types and reflects our commitment to bringing innovative treatment options to patients with cancers driven by EGFR and MET pathways."

Subcutaneous amivantamab was designed to target both epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition (MET) while engaging the immune system, offering a differentiated scientific approach in recurrent or metastatic head and neck squamous cell carcinoma.2 Overexpression of EGFR and MET receptors is seen in 80 to 90 percent of head and neck squamous cell carcinoma tumors and has been implicated in tumor progression and treatment resistance.3

Priority Review supported by pivotal results

The FDA's decision to grant Priority Review is supported by results from the pivotal Phase 1b/2 OrigAMI-4 study, which showed that 42 percent of patients responded to treatment with monotherapy subcutaneous amivantamab, with more than one-third of responders achieving a complete response. The study excluded patients with oropharyngeal squamous cell carcinoma caused by human papillomavirus (HPV), as well as those who had received prior anti-EGFR therapy. The findings were presented at the 2026 American Society for Clinical Oncology (ASCO) and published simultaneously in the Journal of Clinical Oncology.4,5

RYBREVANT FASPRO™ is approved in more than 40 countries, including the United States, Europe, and Japan, as a subcutaneous treatment for non-small cell lung cancer and continues to be evaluated in additional tumor types as part of Johnson & Johnson's broader commitment to advancing transformational oncology therapies.

About the OrigAMI-4 Study

OrigAMI-4 (NCT06385080) is an open-label Phase 1b/2 study evaluating RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) in recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). The study includes six cohorts exploring RYBREVANT FASPRO™ across different treatment settings and regimens.

Cohort 1 evaluated RYBREVANT FASPRO™ as monotherapy in patients with R/M HNSCC who had received prior platinum-based chemotherapy and PD-1/PD-L1 immunotherapy. Patients with HPV-positive oropharyngeal squamous cell carcinoma were excluded, as well as those with prior anti-EGFR therapy.

RYBREVANT FASPRO™ was administered on a weekly schedule during the initial treatment period followed by dosing every three weeks (Q3W), with weight-based dosing adjustments. The primary endpoint across cohorts is overall response rate (ORR), as assessed by investigators, using RECIST v1.1.† 6

About Head and Neck Squamous Cell Carcinoma

Head and neck squamous cell carcinoma (HNSCC) is the most common form of head and neck cancer, a group of cancers that arise in the mouth, throat, voice box, sinuses, nasal cavity, and salivary glands.7 It represents approximately 4.5 percent of all cancers worldwide and is the seventh most common cancer globally.7 Major risk factors include tobacco and alcohol use, as well as infection with high-risk human papillomavirus (HPV).7 Approximately 80 percent of recurrent or metastatic HNSCC are not driven by HPV, and are typically associated with poorer prognosis and reduced response to treatment.7,8,9 Despite advances in surgery, radiation, chemotherapy, and immunotherapy, many patients ultimately progress to advanced recurrent or metastatic disease.10,11

About RYBREVANT FASPRO™ and RYBREVANT®

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) received U.S. FDA approval in December 2025 and is approved in multiple markets worldwide for the treatment of adults with EGFR-mutated non-small cell lung cancer (NSCLC), including those with exon 19 deletions, exon 21 L858R substitution mutations, and exon 20 insertion mutations. It is the only subcutaneous therapy approved for these EGFR-mutated NSCLC populations and may be used as monotherapy or in combination with LAZCLUZE® (lazertinib) or chemotherapy, depending on the specific mutation and treatment setting. For eligible patients, RYBREVANT FASPRO™ offers a once-monthly dosing option following initial weekly dosing. RYBREVANT FASPRO™ is co-formulated with recombinant human hyaluronidase PH20 (rHuPH20), Halozyme's ENHANZE® drug delivery technology.

RYBREVANT FASPRO™ is approved in the U.S. for the same indications as intravenous RYBREVANT® (amivantamab-vmjw) across multiple markets. RYBREVANT® is a first-in-class, fully human bispecific antibody targeting EGFR and MET, designed to inhibit tumor growth while engaging the immune system.

The effectiveness of RYBREVANT FASPRO™ is supported by the established clinical profile of RYBREVANT®, including data from multiple Phase 3 studies such as MARIPOSA, which demonstrated improvements in progression-free and overall survival when used in combination with LAZCLUZE® in first-line advanced EGFR-mutated NSCLC.

The National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology (NCCN Guidelines®)‡ 12 include amivantamab-vmjw (RYBREVANT®) across its FDA-approved treatment settings, including as a Category 1 preferred option in combination with lazertinib (LAZCLUZE®) for first-line treatment of patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R mutations. Subcutaneous amivantamab and hyaluronidase-lpuj (RYBREVANT FASPRO™) may be substituted for IV amivantamab-vmjw (RYBREVANT®) where appropriate. See the latest NCCN Guidelines® for NSCLC for complete information.§ ||

The NCCN Guidelines for Central Nervous System Cancers also include amivantamab (RYBREVANT®)-based regimens, including in combination with lazertinib (LAZCLUZE®), as the only NCCN-preferred combination options for patients with EGFR-mutated NSCLC and brain metastases.§ ||

Beyond NSCLC, RYBREVANT-based therapies are being investigated across other solid tumors, including head and neck and colorectal cancers.

The legal manufacturer for RYBREVANT FASPRO™ and RYBREVANT® is Janssen Biotech, Inc. For more information, visit www.rybrevanthcp.com.

INDICATIONS

RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) and RYBREVANT (amivantamab-vmjw) are indicated:

in combination with LAZCLUZE (lazertinib) for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test. in combination with carboplatin and pemetrexed for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations, whose disease has progressed on or after treatment with an EGFR tyrosine kinase inhibitor. in combination with carboplatin and pemetrexed for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, as detected by an FDA-approved test. as a single agent for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, as detected by an FDA approved test, whose disease has progressed on or after platinum-based chemotherapy. IMPORTANT SAFETY INFORMATION FOR RYBREVANT FASPRO AND RYBREVANT 13,14

CONTRAINDICATIONS

RYBREVANT FASPRO is contraindicated in patients with known hypersensitivity to hyaluronidase or to any of its excipients.

WARNINGS AND PRECAUTIONS

Hypersensitivity and Administration-Related Reactions with RYBREVANT FASPRO

RYBREVANT FASPRO can cause hypersensitivity and administration-related reactions (ARR); signs and symptoms of ARR include dyspnea, flushing, fever, chills, chest discomfort, hypotension, and vomiting. The median time to ARR onset is approximately 2 hours.

RYBREVANT FASPRO with LAZCLUZE

In PALOMA-3 (n=206), all Grade ARR occurred in 13% of patients, including 0.5% Grade 3. Of the patients who experienced ARR, 89% occurred with the initial dose (Week 1, Day 1).

Premedicate with antihistamines, antipyretics, and glucocorticoids and administer RYBREVANT FASPRO as recommended. Monitor patients for any signs and symptoms of administration-related reactions during injection in a setting where cardiopulmonary resuscitation medication and equipment are available. Interrupt RYBREVANT FASPRO injection if ARR is suspected. Resume treatment upon resolution of symptoms or permanently discontinue RYBREVANT FASPRO based on severity.

Infusion-Related Reactions with RYBREVANT

RYBREVANT can cause infusion-related reactions (IRR) including anaphylaxis; signs and symptoms of IRR include dyspnea, flushing, fever, chills, nausea, chest discomfort, hypotension, and vomiting. The median time to IRR onset is approximately 1 hour.

RYBREVANT with LAZCLUZE

In MARIPOSA (n=421), IRRs occurred in 63% of patients, including Grade 3 in 5% and Grade 4 in 1% of patients. IRR-related infusion modifications occurred in 54%, dose reduction in 0.7%, and permanent discontinuation of RYBREVANT in 4.5% of patients.

RYBREVANT with Carboplatin and Pemetrexed

Based on the pooled safety population (n=281), IRRs occurred in 50% of patients including Grade 3 (3.2%) adverse reactions. IRR-related infusion modifications occurred in 46%, and permanent discontinuation of RYBREVANT in 2.8% of patients.

RYBREVANT as a Single Agent

In CHRYSALIS (n=302), IRRs occurred in 66% of patients. IRRs occurred in 65% of patients on Week 1 Day 1, 3.4% on Day 2 infusion, 0.4% with Week 2 infusion, and were cumulatively 1.1% with subsequent infusions. 97% were Grade 1-2, 2.2% were Grade 3, and 0.4% were Grade 4. The median time to onset was 1 hour (range: 0.1 to 18 hours) after start of infusion. IRR-related infusion modifications occurred in 62%, and permanent discontinuation of RYBREVANT in 1.3% of patients.

Premedicate with antihistamines, antipyretics, and glucocorticoids and infuse RYBREVANT as recommended. Administer RYBREVANT via a peripheral line on Week 1 and Week 2 to reduce the risk of IRRs. Monitor patients for signs and symptoms of IRRs in a setting where cardiopulmonary resuscitation medication and equipment are available. Interrupt infusion if IRR is suspected. Reduce the infusion rate or permanently discontinue RYBREVANT based on severity. If an anaphylactic reaction occurs, permanently discontinue RYBREVANT.

Interstitial Lung Disease/Pneumonitis

RYBREVANT FASPRO and RYBREVANT can cause severe and fatal interstitial lung disease (ILD)/pneumonitis.

RYBREVANT FASPRO with LAZCLUZE

In PALOMA-3, ILD/pneumonitis occurred in 6% of patients, including Grade 3 in 1%, Grade 4 in 1.5%, and fatal cases in 1.9% of patients. 5% of patients permanently discontinued RYBREVANT FASPRO and LAZCLUZE due to ILD/pneumonitis.

RYBREVANT with LAZCLUZE

In MARIPOSA, ILD/pneumonitis occurred in 3.1% of patients, including Grade 3 in 1.0% and Grade 4 in 0.2% of patients. There was one fatal case of ILD/pneumonitis and 2.9% of patients permanently discontinued RYBREVANT and LAZCLUZE due to ILD/pneumonitis.

RYBREVANT with Carboplatin and Pemetrexed

Based on the pooled safety population, ILD/pneumonitis occurred in 2.1% of patients with 1.8% of patients experiencing Grade 3 ILD/pneumonitis. 2.1% discontinued RYBREVANT due to ILD/pneumonitis.

RYBREVANT as a Single Agent

In CHRYSALIS, ILD/pneumonitis occurred in 3.3% of patients, with 0.7% of patients experiencing Grade 3 ILD/pneumonitis. Three patients (1%) permanently discontinued RYBREVANT due to ILD/pneumonitis.

Monitor patients for new or worsening symptoms indicative of ILD/pneumonitis (e.g., dyspnea, cough, fever). Immediately withhold RYBREVANT FASPRO or RYBREVANT and LAZCLUZE (when applicable) in patients with suspected ILD/pneumonitis and permanently discontinue if ILD/pneumonitis is confirmed.

Venous Thromboembolic (VTE) Events with Concomitant Use with LAZCLUZE

RYBREVANT FASPRO and RYBREVANT in combination with LAZCLUZE can cause serious and fatal venous thromboembolic (VTE) events, including deep vein thrombosis and pulmonary embolism. Without prophylactic anticoagulation, the majority of these events occurred during the first four months of treatment.

RYBREVANT FASPRO with LAZCLUZE

In PALOMA-3 (n=206), all Grade VTE occurred in 11% of patients and 1.5% were Grade 3. 80% (n=164) of patients received prophylactic anticoagulation at study entry, with an all Grade VTE incidence of 7%. In patients who did not receive prophylactic anticoagulation (n=42), all Grade VTE occurred in 17% of patients. In total, 0.5% of patients had VTE leading to dose reductions of RYBREVANT FASPRO and no patients required permanent discontinuation. The median time to onset of VTEs was 95 days (range: 17 to 390).

RYBREVANT with LAZCLUZE

In MARIPOSA (n=421), VTEs occurred in 36% of patients including Grade 3 in 10% and Grade 4 in 0.5% of patients. On-study VTEs occurred in 1.2% of patients (n=5) while receiving anticoagulation therapy. There were two fatal cases of VTE (0.5%), 9% of patients had VTE leading to dose interruptions of RYBREVANT, and 7% of patients had VTE leading to dose interruptions of LAZCLUZE; 1% of patients had VTE leading to dose reductions of RYBREVANT, and 0.5% of patients had VTE leading to dose reductions of LAZCLUZE; 3.1% of patients had VTE leading to permanent discontinuation of RYBREVANT, and 1.9% of patients had VTE leading to permanent discontinuation of LAZCLUZE. The median time to onset of VTEs was 84 days (range: 6 to 777).

Administer prophylactic anticoagulation for the first four months of treatment. The use of Vitamin K antagonists is not recommended.

Monitor for signs and symptoms of VTE events and treat as medically appropriate. Withhold RYBREVANT FASPRO or RYBREVANT and LAZCLUZE based on severity. Once anticoagulant treatment has been initiated, resume RYBREVANT FASPRO or RYBREVANT and LAZCLUZE at the same dose level at the discretion of the healthcare provider. In the event of VTE recurrence despite therapeutic anticoagulation, permanently discontinue RYBREVANT FASPRO or RYBREVANT. Treatment can continue with LAZCLUZE at the same dose level at the discretion of the healthcare provider. Refer to the LAZCLUZE Prescribing Information for recommended LAZCLUZE dosage modification.

Dermatologic Adverse Reactions

RYBREVANT FASPRO and RYBREVANT can cause severe rash including toxic epidermal necrolysis (TEN), dermatitis acneiform, pruritus and dry skin.

RYBREVANT FASPRO with LAZCLUZE

In PALOMA-3, rash occurred in 80% of patients, including Grade 3 in 17% and Grade 4 in 0.5% of patients. Rash leading to dose reduction occurred in 11% of patients, and RYBREVANT FASPRO was permanently discontinued due to rash in 1.5% of patients.

RYBREVANT with LAZCLUZE

In MARIPOSA, rash occurred in 86% of patients, including Grade 3 in 26% of patients. The median time to onset of rash was 14 days (range: 1 to 556 days). Rash leading to dose interruptions occurred in 37% of patients for RYBREVANT and 30% for LAZCLUZE, rash leading to dose reductions occurred in 23% of patients for RYBREVANT and 19% for LAZCLUZE, and rash leading to permanent discontinuation occurred in 5% of patients for RYBREVANT and 1.7% for LAZCLUZE.

RYBREVANT with Carboplatin and Pemetrexed

Based on the pooled safety population, rash occurred in 82% of patients, including Grade 3 (15%) adverse reactions. Rash leading to dose reductions occurred in 14% of patients, and 2.5% permanently discontinued RYBREVANT and 3.1% discontinued pemetrexed.

RYBREVANT as a Single Agent

In CHRYSALIS, rash occurred in 74% of patients, including Grade 3 in 3.3% of patients. The median time to onset of rash was 14 days (range: 1 to 276 days). Rash leading to dose reduction occurred in 5% and permanent discontinuation due to rash occurred in 0.7% of patients. Toxic epidermal necrolysis occurred in one patient (0.3%). 

When initiating treatment with RYBREVANT FASPRO or RYBREVANT and LAZCLUZE, prophylactic and concomitant medications are recommended to reduce the risk and severity of dermatologic adverse reactions. Instruct patients to limit sun exposure during and for 2 months after treatment. Advise patients to wear protective clothing and use broad spectrum UVA/UVB sunscreen.

If skin reactions develop, administer supportive care including topical corticosteroids and topical and/or oral antibiotics. For Grade 3 reactions, add oral steroids and consider dermatologic consultation. Promptly refer patients presenting with severe rash, atypical appearance or distribution, or lack of improvement within 2 weeks to a dermatologist. For patients receiving RYBREVANT FASPRO or RYBREVANT in combination with LAZCLUZE, withhold, reduce the dose, or permanently discontinue both drugs based on severity. For patients receiving RYBREVANT FASPRO or RYBREVANT as a single agent or in combination with carboplatin and pemetrexed, withhold, dose reduce or permanently discontinue RYBREVANT FASPRO or RYBREVANT based on severity.

Hepatotoxicity

LAZCLUZE in combination with amivantamab can cause severe hepatotoxicity (including increased ALT and AST).

RYBREVANT with LAZCLUZE

In MARIPOSA, based on adverse reaction data, hepatotoxicity occurred in 49% of patients treated with LAZCLUZE, including Grade 3 in 9.3% of patients and Grade 4 in 0.5%. LAZCLUZE was interrupted for an adverse reaction of hepatotoxicity in 8% of patients, the dose was reduced in 1.4% and permanently discontinued in 0.2%.

Perform liver function tests (including ALT, AST, and total bilirubin) before initiation of LAZCLUZE and during treatment, as clinically indicated. Withhold, reduce the dose, or permanently discontinue LAZCLUZE and amivantamab based on severity.

Ocular Toxicity

RYBREVANT FASPRO and RYBREVANT can cause ocular toxicity including keratitis, blepharitis, dry eye symptoms, conjunctival redness, blurred vision, visual impairment, ocular itching, eye pruritus and uveitis.

RYBREVANT FASPRO with LAZCLUZE

In PALOMA-3, all Grade ocular toxicity occurred in 13% of patients, including 0.5% Grade 3.

RYBREVANT with LAZCLUZE

In MARIPOSA, ocular toxicity occurred in 16%, including Grade 3 or 4 ocular toxicity in 0.7% of patients.

RYBREVANT with Carboplatin and Pemetrexed

Based on the pooled safety population, ocular toxicity occurred in 16% of patients. All events were Grade 1 or 2.

RYBREVANT as a Single Agent

In CHRYSALIS, keratitis occurred in 0.7% and uveitis occurred in 0.3% of patients. All events were Grade 1-2.

Promptly refer patients presenting with new or worsening eye symptoms to an ophthalmologist. Withhold, dose reduce or permanently discontinue RYBREVANT FASPRO or RYBREVANT and continue LAZCLUZE based on severity.

Embryo-Fetal Toxicity

Based on animal models, RYBREVANT FASPRO, RYBREVANT and LAZCLUZE can cause fetal harm when administered to a pregnant woman. Verify pregnancy status of females of reproductive potential prior to initiating RYBREVANT FASPRO and RYBREVANT. Advise pregnant women and females of reproductive potential of the potential risk to the fetus. Advise patients of reproductive potential to use effective contraception during treatment and for 3 months after the last dose of RYBREVANT FASPRO or RYBREVANT, and for 3 weeks after the last dose of LAZCLUZE.

ADVERSE REACTIONS

RYBREVANT FASPRO with LAZCLUZE

In PALOMA-3 (n=206), the most common adverse reactions (≥20%) were rash (80%), nail toxicity (58%), musculoskeletal pain (50%), fatigue (37%), stomatitis (36%), edema (34%), nausea (30%), diarrhea (22%), vomiting (22%), constipation (22%), decreased appetite (22%), and headache (21%). The most common Grade 3 or 4 laboratory abnormalities (≥2%) were decreased lymphocyte count (6%), decreased sodium (5%), decreased potassium (5%), decreased albumin (4.9%), increased alanine aminotransferase (3.4%), decreased platelet count (2.4%), increased aspartate aminotransferase (2%), increased gamma-glutamyl transferase (2%), and decreased hemoglobin (2%).

Serious adverse reactions occurred in 33% of patients, with those occurring in ≥2% of patients including ILD/pneumonitis (6%); and pneumonia, VTE and fatigue (2.4% each). Death due to adverse reactions occurred in 5% of patients treated with RYBREVANT FASPRO, including ILD/pneumonitis (1.9%), pneumonia (1.5%), and respiratory failure and sudden death (1% each).

RYBREVANT with LAZCLUZE

In MARIPOSA (n=421), the most common adverse reactions (ARs) (≥20%) were rash (86%), nail toxicity (71%), infusion-related reactions (IRRs) (RYBREVANT) (63%), musculoskeletal pain (47%), stomatitis (43%), edema (43%), VTE (36%), paresthesia (35%), fatigue (32%), diarrhea (31%), constipation (29%), COVID-19 (26%), hemorrhage (25%), dry skin (25%), decreased appetite (24%), pruritus (24%), and nausea (21%). The most common Grade 3 or 4 laboratory abnormalities (≥2%) were decreased albumin (8%), decreased sodium (7%), increased ALT (7%), decreased potassium (5%), decreased hemoglobin (3.8%), increased AST (3.8%), increased GGT (2.6%), and increased magnesium (2.6%).

Serious ARs occurred in 49% of patients, with those occurring in ≥2% of patients including VTE (11%), pneumonia (4%), ILD/pneumonitis and rash (2.9% each), COVID-19 (2.4%), and pleural effusion and IRRs (RYBREVANT) (2.1% each). Fatal ARs occurred in 7% of patients due to death not otherwise specified (1.2%); sepsis and respiratory failure (1% each); pneumonia, myocardial infarction, and sudden death (0.7% each); cerebral infarction, pulmonary embolism (PE), and COVID-19 infection (0.5% each); and ILD/pneumonitis, acute respiratory distress syndrome (ARDS), and cardiopulmonary arrest (0.2% each).

RYBREVANT with Carboplatin and Pemetrexed

In MARIPOSA-2 (n=130), the most common ARs (≥20%) were rash (72%), IRRs (59%), fatigue (51%), nail toxicity (45%), nausea (45%), constipation (39%), edema (36%), stomatitis (35%), decreased appetite (31%), musculoskeletal pain (30%), vomiting (25%), and COVID-19 (21%). The most common Grade 3 to 4 laboratory abnormalities (≥2%) were decreased neutrophils (49%), decreased white blood cells (42%), decreased lymphocytes (28%), decreased platelets (17%), decreased hemoglobin (12%), decreased potassium (11%), decreased sodium (11%), increased alanine aminotransferase (3.9%), decreased albumin (3.8%), and increased gamma-glutamyl transferase (3.1%).

In MARIPOSA-2, serious ARs occurred in 32% of patients, with those occurring in >2% of patients including dyspnea (3.1%), thrombocytopenia (3.1%), sepsis (2.3%), and PE (2.3%). Fatal ARs occurred in 2.3% of patients; these included respiratory failure, sepsis, and ventricular fibrillation (0.8% each).

In PAPILLON (n=151), the most common ARs (≥20%) were rash (90%), nail toxicity (62%), stomatitis (43%), IRRs (42%), fatigue (42%), edema (40%), constipation (40%), decreased appetite (36%), nausea (36%), COVID-19 (24%), diarrhea (21%), and vomiting (21%). The most common Grade 3 to 4 laboratory abnormalities (≥2%) were decreased albumin (7%), increased alanine aminotransferase (4%), increased gamma-glutamyl transferase (4%), decreased sodium (7%), decreased potassium (11%), decreased magnesium (2%), and decreases in white blood cells (17%), hemoglobin (11%), neutrophils (36%), platelets (10%), and lymphocytes (11%).

In PAPILLON, serious ARs occurred in 37% of patients, with those occurring in ≥2% of patients including rash, pneumonia, ILD, PE, vomiting, and COVID-19. Fatal adverse reactions occurred in 7 patients (4.6%) due to pneumonia, cerebrovascular accident, cardio-respiratory arrest, COVID-19, sepsis, and death not otherwise specified.

RYBREVANT as a Single Agent

In CHRYSALIS (n=129), the most common ARs (≥20%) were rash (84%), IRR (64%), paronychia (50%), musculoskeletal pain (47%), dyspnea (37%), nausea (36%), fatigue (33%), edema (27%), stomatitis (26%), cough (25%), constipation (23%), and vomiting (22%). The most common Grade 3 to 4 laboratory abnormalities (≥2%) were decreased lymphocytes (8%), decreased albumin (8%), decreased phosphate (8%), decreased potassium (6%), increased alkaline phosphatase (4.8%), increased glucose (4%), increased gamma-glutamyl transferase (4%), and decreased sodium (4%).

Serious ARs occurred in 30% of patients, with those occurring in ≥2% of patients including PE, pneumonitis/ILD, dyspnea, musculoskeletal pain, pneumonia, and muscular weakness. Fatal adverse reactions occurred in 2 patients (1.5%) due to pneumonia and 1 patient (0.8%) due to sudden death.

LAZCLUZE DRUG INTERACTIONS

Avoid concomitant use of LAZCLUZE with strong and moderate CYP3A4 inducers. Consider an alternate concomitant medication with no potential to induce CYP3A4.

Monitor for adverse reactions associated with a CYP3A4 or BCRP substrate where minimal concentration changes may lead to serious adverse reactions, as recommended in the approved product labeling for the CYP3A4 or BCRP substrate.

Please see full Prescribing Information for RYBREVANT FASPRO, RYBREVANT and LAZCLUZE.

cp-491009v2

About Johnson & Johnson

At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow and profoundly impact health for humanity. Learn more at https://www.jnj.com/ or at www.innovativemedicine.jnj.com. Follow us at @JNJInnovMed.

Cautions Concerning Forward-Looking Statements

This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding product development and the potential benefits and treatment impact of RYBREVANT-based regimens. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's most recent Annual Report on Form 10-K, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com, www.investor.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.

† RECIST (version 1.1) refers to Response Evaluation Criteria in Solid Tumors, which is a standard way to measure how well
solid tumors respond to treatment and is based on whether tumors shrink, stay the same or get bigger.

‡ The NCCN content does not constitute medical advice and should not be used in place of seeking professional medical advice, diagnosis or treatment by licensed practitioners. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

§ See the NCCN Guidelines for detailed recommendations, including other treatment options.

|| The NCCN Guidelines for NSCLC provide recommendations for certain individual biomarkers that should be tested and recommend testing techniques but do not endorse any specific commercially available biomarker assays or commercial laboratories.

______________________________________
1 U.S. Food & Drug Administration. Priority Review. Accessed July 2026. https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/priority-review
2 Harrington KJ, Rosenberg AJ, Yang MH, et al. Subcutaneous amivantamab in recurrent/metastatic head and neck squamous cell cancer after disease progression on checkpoint inhibitor and chemotherapy: Preliminary results from the phase 1b/2 OrigAMI-4 study. Oral Oncol. 2025;171:107791.
3 Kalyankrishna S, Grandis JR. Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol. 2006;24(17):2666–2672.
4 Burtness B, Rosenberg AJ, Calderon B, et al. Amivantamab in recurrent/metastatic head and neck squamous cell cancer after disease progression on immune checkpoint inhibitor and chemotherapy. Pivotal results from the phase 1b/2 OrigAMI-4 study. Presented at: The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting; May 31, 2026; Chicago, Illinois.
5 Burtness B, Rosenberg AJ, Calderon B, et al. Amivantamab in recurrent/metastatic head and neck squamous cell carcinoma after checkpoint inhibitor and chemotherapy: pivotal results from the phase 1b/2 OrigAMI-4 study. J Clin Onc. May 31, 2026. doi:10.1200/JCO-26-01042.
6 ClinicalTrials.gov. A study of amivantamab alone or in addition to other treatment agents in participants with recurrent/metastatic head and neck cancer (OrigAMI-4). Accessed July 2026. https://clinicaltrials.gov/study/NCT06385080?term=OrigAMI-4&limit=10&rank=1.
7 Barsouk A, Aluru JS, Rawla P, Saginala K, Barsouk A. Epidemiology, risk factors, and prevention of head and neck squamous cell carcinoma. Med Sci (Basel). 2023;11(2):42. Published 2023 Jun 13. doi:10.3390/medsci11020042
8 Haddad RI, Ferrarotto R, Guo Y, et al. OrigAMI-5: A randomized, phase 3 study of amivantamab plus pembrolizumab and carboplatin vs standard of care pembrolizumab plus platinum and 5-fluorouracil as first-line treatment in recurrent/metastatic head and neck cancer. Presented at: The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting; May 30, 2026; Chicago, Illinois.
9 Ghiani L, Chiocca S. High risk-human apillomavirus in HNSCC: Present and future challenges for pigenetic therapies. Int J Mol Sci. 2022;23(7):3483. doi.org/10.3390/ijms23073483
10 Ferris RL, Blumenschein Jr G, Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and eck. New Eng J Med. 2016;375(19):1856-1867. doi:10.1056/NEJMoa1602252
11 Wise-Draper TM, Bahig H, Tonneau M, Karivedu V, Burtness B. Current therapy for metastatic head and neck ancer: Evidence, opportunities, and challenges. Am Soc Clin Oncol Educ Book. 2022;42:1-14. doi:10.1200/EDBK_350442
12 Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non-Small Cell Lung Cancer V.3.2026 © National Comprehensive Cancer Network, Inc. All rights reserved. Accessed July 2026.To view the most recent and complete version of the guideline, go online to NCCN.org.
13 RYBREVANT FASPRO [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.
14 RYBREVANT [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.

SOURCE Johnson & Johnson

Xerox Holdings Corporation (XRX - Free Report) came out with quarterly earnings of $0.36 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to a loss of $0.64 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +500.00%. A quarter ago, it was expected that this company would post a loss of $0.2 per share when it actually produced a loss of $0.11, delivering a surprise of +45%.

Over the last four quarters, the company has surpassed consensus EPS estimates three times.

Xerox, which belongs to the Zacks Office Supplies industry, posted revenues of $1.92 billion for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 0.96%. This compares to year-ago revenues of $1.58 billion. The company has topped consensus revenue estimates two times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Xerox shares have added about 11.4% since the beginning of the year versus the S&P 500's gain of 6.9%.

What's Next for Xerox?While Xerox has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Xerox was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.10 on $1.88 billion in revenues for the coming quarter and $0.03 on $7.59 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Office Supplies is currently in the top 38% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Another stock from the broader Zacks Industrial Products sector, Astec Industries (ASTE - Free Report) , has yet to report results for the quarter ended June 2026. The results are expected to be released on August 5.

This maker of equipment for building, paving and mining is expected to post quarterly earnings of $1.05 per share in its upcoming report, which represents a year-over-year change of +19.3%. The consensus EPS estimate for the quarter has been revised 1.4% higher over the last 30 days to the current level.

Astec Industries' revenues are expected to be $402.5 million, up 21.9% from the year-ago quarter.

Arete Wealth Advisors LLC increased its stake in PayPal Holdings, Inc. (NASDAQ:PYPL – Free Report) by 273.2% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 24,804 shares of the credit services provider’s stock after purchasing an additional 18,158 shares during the period. Arete Wealth Advisors LLC’s holdings in PayPal were worth $1,121,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of PYPL. Vanguard Group Inc. boosted its stake in PayPal by 6.5% during the 4th quarter. Vanguard Group Inc. now owns 90,376,927 shares of the credit services provider’s stock worth $5,276,205,000 after acquiring an additional 5,534,462 shares during the last quarter. Rule One Partners LLC bought a new stake in PayPal in the fourth quarter valued at approximately $2,043,000. Step Capital Management Pte. Ltd. bought a new position in shares of PayPal during the fourth quarter worth $6,130,000. Swiss National Bank boosted its position in shares of PayPal by 4.9% during the first quarter. Swiss National Bank now owns 2,608,600 shares of the credit services provider’s stock worth $117,987,000 after purchasing an additional 121,400 shares in the last quarter. Finally, Easterly Investment Partners LLC grew its holdings in shares of PayPal by 705.2% in the 4th quarter. Easterly Investment Partners LLC now owns 100,651 shares of the credit services provider’s stock valued at $5,876,000 after buying an additional 88,151 shares during the period. Institutional investors and hedge funds own 68.32% of the company’s stock.

Wall Street Analysts Forecast Growth Several research analysts have weighed in on the company. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and set a $45.00 target price on shares of PayPal in a report on Wednesday. Citigroup raised their price target on PayPal from $48.00 to $61.00 and gave the stock a “neutral” rating in a research report on Wednesday. The Goldman Sachs Group set a $50.00 price objective on PayPal in a report on Tuesday. Clear Str raised PayPal to a “hold” rating in a research note on Thursday, July 16th. Finally, Keefe, Bruyette & Woods raised their target price on shares of PayPal from $55.00 to $70.00 and gave the stock an “outperform” rating in a report on Wednesday. Nine research analysts have rated the stock with a Buy rating, thirty-four have assigned a Hold rating and four have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, PayPal presently has a consensus rating of “Hold” and an average target price of $55.50.

View Our Latest Stock Report on PayPal

PayPal Trading Up 0.1% NASDAQ PYPL opened at $58.35 on Thursday. PayPal Holdings, Inc. has a 52 week low of $38.46 and a 52 week high of $79.21. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.26 and a current ratio of 1.29. The stock’s 50 day moving average price is $46.50 and its two-hundred day moving average price is $47.02. The stock has a market capitalization of $51.47 billion, a price-to-earnings ratio of 11.03, a PEG ratio of 1.46 and a beta of 1.33.

PayPal (NASDAQ:PYPL – Get Free Report) last issued its quarterly earnings results on Tuesday, July 28th. The credit services provider reported $1.38 earnings per share for the quarter, topping the consensus estimate of $1.28 by $0.10. PayPal had a net margin of 14.36% and a return on equity of 24.39%. The company had revenue of $8.68 billion during the quarter, compared to analysts’ expectations of $8.47 billion. During the same period last year, the business earned $1.40 EPS. The business’s quarterly revenue was up 4.8% on a year-over-year basis. As a group, analysts anticipate that PayPal Holdings, Inc. will post 5.31 earnings per share for the current fiscal year.

PayPal Announces Dividend The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 25th. Stockholders of record on Friday, September 4th will be paid a dividend of $0.14 per share. This represents a $0.56 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date is Friday, September 4th. PayPal’s dividend payout ratio is currently 10.51%.

Insider Transactions at PayPal In related news, insider Suzan Kereere sold 3,379 shares of the company’s stock in a transaction dated Wednesday, June 3rd. The stock was sold at an average price of $42.79, for a total transaction of $144,587.41. Following the sale, the insider owned 30,983 shares in the company, valued at approximately $1,325,762.57. This represents a 9.83% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Frank Keller sold 4,612 shares of the stock in a transaction that occurred on Wednesday, June 3rd. The shares were sold at an average price of $42.54, for a total value of $196,194.48. Following the transaction, the insider directly owned 41,567 shares of the company’s stock, valued at $1,768,260.18. This trade represents a 9.99% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 8,543 shares of company stock valued at $364,325. Company insiders own 0.63% of the company’s stock.

PayPal News Summary Here are the key news stories impacting PayPal this week:

Positive Sentiment: PayPal reported second-quarter adjusted EPS of $1.38, above the $1.28 consensus, while revenue rose 4.8% year over year to $8.68 billion, exceeding the $8.47 billion estimate. Total payment volume increased 10% to $486.4 billion. PayPal Reports Second Quarter 2026 Results Positive Sentiment: Management raised its full-year adjusted earnings outlook to $5.38 per share and highlighted improving branded checkout, Venmo growth, cost savings and investments in AI, digital identity and stablecoin-enabled payments. The guidance increase supports the view that CEO Enrique Lores’ turnaround is gaining traction. PayPal’s Q2 Earnings Call Focuses on Checkout Stability Positive Sentiment: Several analysts raised their price targets following the results. Keefe, Bruyette & Woods moved its target to $70 and upgraded PayPal to Outperform, while JPMorgan raised its target to $65 and retained a Neutral rating. PayPal also declared a quarterly dividend of $0.14 per share and repurchased approximately $1.5 billion of stock. Neutral Sentiment: Takeover speculation remains a catalyst. Stripe and Advent International reportedly offered $60.50 per share, but PayPal’s board viewed the proposal as too low. The company appears open to a higher offer while continuing its standalone turnaround, leaving investors to balance potential deal value against execution of the recovery plan. PayPal Leaves the Door Open to a Higher Takeover Offer Negative Sentiment: Wall Street remains divided. Goldman Sachs issued a Sell warning, while Wells Fargo, Baird, Canaccord, TD Cowen and other firms maintained Neutral or Hold ratings, citing slower branded-checkout growth, margin pressure from investment spending, competitive threats and execution risk. Several targets remain below the current share price. PayPal Stock Splits Wall Street PayPal Profile (Free Report)

PayPal Holdings, Inc operates a global digital payments platform that enables consumers and merchants to send and receive payments online, on mobile devices and at the point of sale. The company provides a broad set of payment solutions, including a digital wallet, merchant payment processing, checkout services, invoicing and fraud-management tools. PayPal’s platform is designed to support e-commerce, in-person retail and person-to-person transfers, targeting both individual consumers and businesses of varying sizes.

Key products and services in PayPal’s portfolio include the PayPal wallet and checkout ecosystem, the Venmo peer-to-peer mobile app, Braintree’s developer-focused payment gateway, Xoom for international money transfers, and PayPal Credit and buy-now-pay-later options.

See Also Five stocks we like better than PayPal Why SK hynix Could Be the Best AI Chip Stock to Buy Now Seagate Technology Stock Surges as Earnings Beat Silences AI Doubters Alphabet Is Down 18% From Its High After a Stellar Quarter—Overdone, or More Downside Ahead? Why Bloom Energy May Be the Most Important AI Infrastructure Stock Want to see what other hedge funds are holding PYPL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PayPal Holdings, Inc. (NASDAQ:PYPL – Free Report).

Receive News & Ratings for PayPal Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PayPal and related companies with MarketBeat.com's FREE daily email newsletter.

The Pfizer logo is seen in this illustration taken August 3, 2025. REUTERS/Dado Ruvic/Illustration/File Photo Purchase Licensing Rights, opens new tab

CompaniesJuly 30 (Reuters) - Pfizer (PFE.N), opens new tab said on Thursday its oral drug helped restore skin color in patients with a common form of vitiligo in ​two late-stage trials, paving the way for regulatory submissions seeking ‌approval in the autoimmune skin disease.

Here are the details:

Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here.

The U.S. drugmaker was testing Litfulo in patients with nonsegmental vitiligo, the most common type of the ​disease, which causes patches of skin to lose pigment.

Pfizer said ​both studies showed significantly more patients treated with the ⁠drug achieved at least a 75% improvement in facial repigmentation and ​at least a 50% improvement in total-body repigmentation after 52 weeks ​compared with those given placebo.

"Litfulo could become a new oral systemic treatment option for adults living with NSV, significantly improving and potentially maintaining facial and total ​body repigmentation," Michael Vincent, Pfizer's chief inflammation and immunology officer, said ​in a statement.

The trials, which enrolled a combined 2,174 patients across 50 mg ‌and ⁠100 mg once-daily doses, were the largest late-stage programs to evaluate an oral treatment for nonsegmental vitiligo, the company said.

The drug works by blocking specific proteins inside immune cells, called JAK3 and TEC ​family kinases, which helps ​stop the ⁠immune system from attacking the pigment-producing cells in the skin.

Litfulo is already approved in several countries, including ​the United States, for severe alopecia areata, an ​autoimmune disorder ⁠that causes hair loss.

Pfizer said the drug's safety profile in vitiligo patients was consistent with that seen in studies of alopecia areata, with ⁠no ​new safety signals identified.

Pfizer plans to submit ​the data to health regulators globally to seek approval for the treatment in adults ​with nonsegmental vitiligo.

Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore

Our Standards: The Thomson Reuters Trust Principles., opens new tab

Integrations can help Oracle Fusion Cloud Applications and Oracle NetSuite customers automate processes, accelerate decisions, and securely execute mission-critical work

Gemini models, including 3.1 Flash-Lite and 3.5 Flash, enable Oracle customers to deploy Agentic applications and enhance AI price-performance

, /PRNewswire/ -- Oracle and Google Cloud have expanded their partnership to bring Google's Gemini models to Oracle's extensive portfolio of enterprise applications. The partnership builds on customers' existing access to Gemini models through Oracle Cloud Infrastructure (OCI) Enterprise AI and is planned to make Gemini models available in Oracle AI Agent Studio for Fusion Applications, a complete development platform that enables organizations to build, connect, execute, and run AI automation and agentic applications using reusable Oracle, partner, and external agents. In addition, Oracle plans to use Gemini models for embedded AI use cases in Oracle Fusion Applications and Oracle NetSuite.

"Organizations around the world trust Google Cloud's full AI stack to power critical enterprise workflows and agents," said Satish Thomas, Vice President, Google Cloud. "Our expanded partnership with Oracle is designed to make it easier for organizations to use Gemini in the applications and agentic workflows they rely on to automate workflows, accelerate decisions, and drive outcomes."

"Our partnership with Oracle brings Google's most capable AI models directly into the core application workflows global businesses rely on every day," said Kevin Ichhpurani, President, Global Partner Ecosystem at Google Cloud. "Together, we are making it seamless for enterprises to apply powerful and cost-efficient AI directly where business decisions happen."

With access to Google's Gemini models in Oracle AI Agent Studio, customers and partners will be able to gain more choice when building Fusion-native agents and agentic applications, and expanded multi-modal capabilities. For example, customers and partners will be able to access Gemini 3.1 Flash Lite, a high-efficiency model engineered for optimal price-performance, and Gemini 3.5 Flash for more complex reasoning and specialized tasks, including video and presentation creation, in addition to models from other leading providers.

"To achieve the best business outcomes, organizations need the flexibility to choose the AI model best suited to each problem," said Chris Leone, executive vice president, applications development, Oracle. "By bringing Gemini to Oracle AI Agent Studio for Fusion Applications, we are giving customers and partners greater choice as they build and extend agents and agentic applications that reason through complex, real-world business challenges. Oracle Fusion Applications then turn that reasoning into action through governed workflows, approvals, and transactions."

Oracle also plans to use Gemini models for embedded AI use cases in Oracle Fusion Applications and NetSuite. In each case, Oracle expects to tap into Gemini where it can deliver optimal price-performance for specific customer scenarios.

"AI is at the core of how customers use and experience NetSuite and choosing the right model for the right use case is critical to helping them get more value from AI," said Evan Goldberg, founder and executive vice president, Oracle NetSuite. "As we evaluate various AI use cases in NetSuite, we are working with leading large language models, like Google's Gemini, to help customers improve visibility, automate work, and move from insight to action within NetSuite."

The addition of Gemini models to Oracle's enterprise applications complements Oracle's existing developer offerings, which provide access to Gemini models available via OCI Enterprise AI through integration with Gemini Enterprise Agent Platform. Together, Oracle and Google Cloud are giving customers broader access to powerful, secure, and cost-effective Gemini models that can support AI agents, accelerate development and data integration, and drive innovation across industries.

About Oracle Fusion Cloud Applications

Oracle Fusion Cloud Applications provide an integrated suite of AI-powered cloud applications that enable organizations to execute faster, make smarter decisions, and lower costs. Oracle Fusion Applications include:

Oracle Fusion Cloud Enterprise Resource Planning (ERP): Provides a comprehensive suite of AI-powered finance and operations applications that help organizations increase productivity, reduce costs, expand insights, improve decision-making, and enhance controls. Oracle Fusion Cloud Human Capital Management (HCM): Provides a unified AI-powered HR platform that connects people, processes, and data to help organizations automate the employee lifecycle, enhance the employee experience, and drive better business outcomes with a human-agent workforce. Oracle Fusion Cloud Supply Chain & Manufacturing (SCM): Provides a unified AI-powered platform that integrates supply chain and operations processes and helps organizations enhance resilience and quickly adapt to market changes. Oracle Fusion Cloud Customer Experience (CX): Provides a suite of AI-powered applications that helps organizations manage marketing, sales, and service processes to win business, build stronger customer relationships, and improve customer experiences. About Oracle NetSuite

For more than 25 years, Oracle NetSuite has helped organizations of all sizes reach their goals faster and more efficiently. NetSuite provides an integrated business system with embedded AI that delivers powerful financial management, supply chain, customer experience, and HR capabilities. Relied on by more than 44,000 customers in 220 countries and dependent territories, NetSuite is the #1 AI cloud enterprise resource planning (ERP) solution.

About Oracle

Oracle offers integrated suites of applications plus secure, autonomous infrastructure in the Oracle Cloud. For more information about Oracle (NYSE: ORCL), please visit us at www.oracle.com.

Trademarks 

Oracle, Java, MySQL, and NetSuite are registered trademarks of Oracle Corporation. NetSuite was the first cloud company—ushering in the new era of cloud computing.

Future Product Disclaimer

The preceding is intended to outline our general product direction. It is for informational purposes only and may not be incorporated into any contract. The development, release, timing, and pricing of any features or functionality described for Oracle's products may change at Oracle Corporation's sole discretion.

About Google Cloud

Google Cloud offers a powerful, optimized AI stack — including AI infrastructure, leading models like Gemini, data management capabilities, multicloud security solutions, developer tools and platform, as well as agents and applications — that enables organizations to transform their business for the Agentic Era. Customers in more than 200 countries and territories turn to Google Cloud as their trusted technology partner.

SOURCE Oracle

Key Takeaways LyondellBasell reports second-quarter 2026 results before the opening bell on July 31. LYB sees North America and Europe benefiting from stronger demand, exports and higher operating rates. LyondellBasell targets $500M incremental cash flow in 2026 through cost and portfolio initiatives. LyondellBasell Industries N.V. (LYB - Free Report) is set to release second-quarter 2026 results before the opening bell on Friday. 

LyondellBasell missed the Zacks Consensus Estimate for earnings in two of the trailing four quarters, and beat it twice, with the average negative earnings surprise being 47.2%.

The company is expected to have faced headwinds from higher feedstock costs amid improved seasonal demand in the second quarter.

LYB's shares are up 4.4% in the past year compared with the Zacks Chemicals Diversified industry’s 1.7% rise.

Image Source: Zacks Investment Research

Let’s see how things are shaping up for this announcement. 

What Our Model Unveils for LYB Our proven model doesn’t predict an earnings beat for LYB this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. That is not the case here. 

Earnings ESP: Earnings ESP for LYB is -5.07%. The Zacks Consensus Estimate for the second quarter is currently pegged at $3.56 per share. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.

Zacks Rank: LYB currently carries a Zacks Rank #3. 

What Do LYB’s Revenue Estimates Say ?The Zacks Consensus Estimate for second-quarter consolidated revenues for LYB is currently pegged at $8,900.6 million, implying a year-over-year increase of 16.2%. 

For the Olefins and Polyolefins – Americas division, the consensus estimate is $3,456 million, suggesting a year-over-year rise of 26.5%. The same for the Olefins and Polyolefins – Europe, Asia & International division is pegged at $3,243 million, implying a 24.7% increase from last year’s tally. 

For LYB’s Advanced Polymer Solutions (APS) segment, the Zacks Consensus Estimate for second-quarter revenues is $973 million, suggesting a 5.1% rise year over year. 

The consensus estimate for the Intermediaries and Derivatives segment’s revenues is pinned at $2,606 million, suggesting a 12.2% rise from the year-ago reported figure. 

The same for the Technology segment's revenues is pegged at $163 million, indicating a 12.4% fall from a year ago. 

Factors at Play for LYB LyondellBasell is expected to have benefited from a stronger operating environment in the second quarter, supported by tightening global petrochemical supply, improving pricing and higher operating rates. Ongoing geopolitical tensions in the Middle East have disrupted energy and petrochemical supply chains, reducing production and exports from key regions. Management expects these supply disruptions to persist for several quarters, creating structurally tighter supply-demand balances across polyethylene, polypropylene and other petrochemical products. This environment is expected to have driven stronger export demand, higher product prices and improved margins. 

North America is expected to have been LYB's strongest growth driver in the second quarter, supported by improving seasonal demand, higher polyethylene and polypropylene prices, and robust export demand. Tight global supply is expected to have kept the company's North American assets running at around 90% of nameplate capacity, boosting volumes and margins.  

Europe is expected to have seen improved demand, stronger polymer margins and an operating rate of around 80%, supported by lower imports from the Middle East and China. The recent sale of four European assets might have further strengthened LYB's portfolio and improved profitability. 

The Intermediates & Derivatives segment is expected to have benefited from stronger seasonal demand, improved oxyfuels margins and the restart of the Bayport PO/TBA facility by the end of the second quarter. The Bayport outage reduced first-quarter EBITDA by around $40 million and is estimated to have negatively impacted earnings by roughly $25 million per week while the asset remained offline, making its restart a key catalyst for second-quarter profitability. 

The APS segment is expected to have faced mixed conditions. While automotive and other durable goods markets remain soft, the company is actively passing through higher raw material, energy and logistics costs to customers. Although contractual pricing mechanisms may temporarily delay margin recovery, customer demand has remained relatively resilient in packaging and other essential end markets, supporting the company's long-term transformation strategy. 

LYB continues to execute initiatives aimed at strengthening profitability and cash generation. The company remains focused on its portfolio transformation, disciplined capital allocation and cost-reduction efforts under its Cash Improvement Plan. Management is targeting $500 million of incremental cash flow in 2026, bringing cumulative improvements since 2025 to $1.3 billion. Lower fixed costs, improved working capital management and ongoing productivity initiatives are expected to have further supported earnings in the June quarter despite higher raw material and logistics costs.  

LyondellBasell Industries N.V. Price and EPS SurpriseBasic Materials Stocks That Warrant a LookHere are some companies in the basic materials space you may want to consider, as our model shows they have the right combination of elements to post an earnings beat this quarter: 

The Chemours Company (CC - Free Report) , scheduled to release earnings on Aug. 4, has an Earnings ESP of +27.17% and carries a Zacks Rank #1. You can see the complete list of today’s Zacks #1 Rank stocks here. 

The consensus estimate for CC’s second-quarter earnings is currently pegged at 43 cents per share. 

Avient Corporation (AVNT - Free Report) , scheduled to release earnings on Aug. 6, has an Earnings ESP of +0.87% and carries a Zacks Rank #2 at present. 

The consensus mark for AVNT’s second-quarter earnings is currently pegged at 89 cents per share. 

Ternium S.A. (TX - Free Report) , slated to release earnings on Aug. 4, has an Earnings ESP of +21.4%. 

The Zacks Consensus Estimate for TX's second-quarter earnings is currently pegged at $1.29 per share. TX currently carries a Zacks Rank #1.

Posted by Defense World Staff on Jul 30th, 2026

Amundi increased its position in shares of Simon Property Group, Inc. (NYSE:SPG – Free Report) by 19.0% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,990,741 shares of the real estate investment trust’s stock after purchasing an additional 317,901 shares during the quarter. Amundi owned 0.61% of Simon Property Group worth $371,334,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently bought and sold shares of the company. Stance Capital LLC acquired a new position in shares of Simon Property Group during the 3rd quarter worth $26,000. Wilkerson Advisory Group LLC purchased a new position in Simon Property Group during the 4th quarter valued at about $29,000. SHP Wealth Management acquired a new position in Simon Property Group during the fourth quarter worth about $34,000. Dynamic Wealth Strategies LLC raised its position in Simon Property Group by 195.8% during the first quarter. Dynamic Wealth Strategies LLC now owns 210 shares of the real estate investment trust’s stock worth $39,000 after acquiring an additional 139 shares during the last quarter. Finally, Cullen Frost Bankers Inc. lifted its holdings in shares of Simon Property Group by 79.3% in the fourth quarter. Cullen Frost Bankers Inc. now owns 251 shares of the real estate investment trust’s stock valued at $46,000 after purchasing an additional 111 shares in the last quarter. 93.01% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth Several analysts have recently commented on SPG shares. Stifel Nicolaus increased their price target on shares of Simon Property Group from $185.00 to $194.00 and gave the company a “hold” rating in a research report on Tuesday, May 12th. Weiss Ratings raised Simon Property Group from a “buy (b)” rating to a “buy (b+)” rating in a research note on Tuesday, July 14th. Citigroup upped their target price on Simon Property Group from $189.00 to $205.00 and gave the company a “neutral” rating in a research note on Thursday, May 14th. Jefferies Financial Group upgraded Simon Property Group to a “strong-buy” rating in a report on Friday, June 26th. Finally, Evercore set a $215.00 price target on Simon Property Group in a report on Tuesday, July 7th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and eleven have issued a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $216.14.

Check Out Our Latest Stock Analysis on SPG

Simon Property Group Stock Down 0.5% Shares of SPG opened at $235.44 on Thursday. Simon Property Group, Inc. has a fifty-two week low of $159.70 and a fifty-two week high of $238.50. The company’s fifty day moving average is $217.90 and its two-hundred day moving average is $202.78. The firm has a market cap of $76.35 billion, a PE ratio of 16.36, a price-to-earnings-growth ratio of 3.06 and a beta of 1.29. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 4.68.

Simon Property Group (NYSE:SPG – Get Free Report) last announced its quarterly earnings results on Monday, May 11th. The real estate investment trust reported $1.48 earnings per share for the quarter, topping analysts’ consensus estimates of $1.46 by $0.02. Simon Property Group had a net margin of 70.60% and a return on equity of 104.54%. The firm had revenue of $1.76 billion during the quarter, compared to analysts’ expectations of $1.54 billion. During the same period in the prior year, the company earned $2.95 EPS. The firm’s revenue was up 19.3% on a year-over-year basis. Simon Property Group has set its FY 2026 guidance at 13.100-13.250 EPS. Analysts forecast that Simon Property Group, Inc. will post 13.21 earnings per share for the current year.

Simon Property Group Increases Dividend The company also recently announced a quarterly dividend, which was paid on Tuesday, June 30th. Stockholders of record on Tuesday, June 9th were given a dividend of $2.25 per share. The ex-dividend date of this dividend was Tuesday, June 9th. This is an increase from Simon Property Group’s previous quarterly dividend of $2.20. This represents a $9.00 dividend on an annualized basis and a dividend yield of 3.8%. Simon Property Group’s dividend payout ratio is presently 62.54%.

Insiders Place Their Bets In other Simon Property Group news, Director Larry C. Glasscock acquired 397 shares of the stock in a transaction on Tuesday, June 30th. The stock was purchased at an average price of $223.38 per share, for a total transaction of $88,681.86. Following the purchase, the director directly owned 45,902 shares in the company, valued at $10,253,588.76. This trade represents a 0.87% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Daniel C. Smith acquired 372 shares of the company’s stock in a transaction on Tuesday, June 30th. The shares were acquired at an average price of $223.31 per share, for a total transaction of $83,071.32. Following the completion of the acquisition, the director directly owned 34,480 shares in the company, valued at $7,699,728.80. The trade was a 1.09% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last ninety days, insiders bought 2,387 shares of company stock valued at $533,056. Corporate insiders own 8.73% of the company’s stock.

Simon Property Group Company Profile (Free Report)

Simon Property Group, Inc (NYSE: SPG) is a publicly traded real estate investment trust (REIT) that owns, develops and manages retail real estate properties. Its core business activities include acquisition, development, leasing and property management of regional malls, outlet centers and mixed‑use retail destinations. The company operates retail brands that include high‑profile regional shopping centers and the Premium Outlets platform, and it provides services such as tenant leasing, marketing, property operations and capital projects to optimize asset performance.

Simon’s portfolio spans a broad mix of enclosed malls, open‑air centers, outlet properties and mixed‑use developments, and the company pursues redevelopment and repositioning to adapt properties to changing consumer and retail trends.

Featured Articles Five stocks we like better than Simon Property Group Why SK hynix Could Be the Best AI Chip Stock to Buy Now Seagate Technology Stock Surges as Earnings Beat Silences AI Doubters Alphabet Is Down 18% From Its High After a Stellar Quarter—Overdone, or More Downside Ahead? Why Bloom Energy May Be the Most Important AI Infrastructure Stock Want to see what other hedge funds are holding SPG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Simon Property Group, Inc. (NYSE:SPG – Free Report).

Receive News & Ratings for Simon Property Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Simon Property Group and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEArrowstreet Capital Limited Partnership Buys 289,458 Shares of Eastern Bankshares, Inc. $EBC

NEXT HEADLINE »Amundi Acquires 491,758 Shares of Pentair plc $PNR

Regeneron (REGN - Free Report) came out with quarterly earnings of $14.29 per share, beating the Zacks Consensus Estimate of $10 per share. This compares to earnings of $12.89 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +42.90%. A quarter ago, it was expected that this biopharmaceutical company would post earnings of $8.52 per share when it actually produced earnings of $9.47, delivering a surprise of +11.15%.

Over the last four quarters, the company has surpassed consensus EPS estimates four times.

Regeneron, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $4.29 billion for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 11.74%. This compares to year-ago revenues of $3.68 billion. The company has topped consensus revenue estimates four times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Regeneron shares have lost about 9.9% since the beginning of the year versus the S&P 500's gain of 6.9%.

What's Next for Regeneron?While Regeneron has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Regeneron was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $12.58 on $4.1 billion in revenues for the coming quarter and $45.50 on $15.75 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 37% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Another stock from the same industry, Geron (GERN - Free Report) , has yet to report results for the quarter ended June 2026. The results are expected to be released on August 5.

This drugmaker is expected to post quarterly loss of $0.01 per share in its upcoming report, which represents a year-over-year change of +50%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

Geron's revenues are expected to be $55.01 million, up 12.2% from the year-ago quarter.

Posted by Defense World Staff on Jul 30th, 2026

Altshuler Shaham Ltd lifted its position in shares of Broadcom Inc. (NASDAQ:AVGO – Free Report) by 238.1% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 434,535 shares of the semiconductor manufacturer’s stock after purchasing an additional 306,010 shares during the period. Broadcom accounts for approximately 2.1% of Altshuler Shaham Ltd’s investment portfolio, making the stock its 15th biggest holding. Altshuler Shaham Ltd’s holdings in Broadcom were worth $134,493,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in the company. Fullerton Advisors LLC boosted its position in shares of Broadcom by 1.3% in the first quarter. Fullerton Advisors LLC now owns 1,989 shares of the semiconductor manufacturer’s stock valued at $616,000 after acquiring an additional 25 shares during the period. NORTHSTAR ASSET MANAGEMENT Co grew its stake in shares of Broadcom by 0.5% in the first quarter. NORTHSTAR ASSET MANAGEMENT Co now owns 5,350 shares of the semiconductor manufacturer’s stock valued at $1,656,000 after acquiring an additional 25 shares in the last quarter. RFG Holdings Inc. increased its position in Broadcom by 0.3% during the first quarter. RFG Holdings Inc. now owns 8,499 shares of the semiconductor manufacturer’s stock worth $2,631,000 after acquiring an additional 26 shares during the period. Yukon Wealth Management Inc. increased its position in Broadcom by 1.1% during the first quarter. Yukon Wealth Management Inc. now owns 2,501 shares of the semiconductor manufacturer’s stock worth $774,000 after acquiring an additional 26 shares during the period. Finally, Capital Planning LLC raised its stake in Broadcom by 0.7% in the 1st quarter. Capital Planning LLC now owns 4,044 shares of the semiconductor manufacturer’s stock worth $1,252,000 after purchasing an additional 28 shares in the last quarter. 76.43% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets In other Broadcom news, Director Harry L. You acquired 1,000 shares of the company’s stock in a transaction that occurred on Thursday, June 11th. The stock was acquired at an average cost of $373.57 per share, for a total transaction of $373,570.00. Following the transaction, the director directly owned 38,466 shares in the company, valued at $14,369,743.62. This represents a 2.67% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Mark David Brazeal sold 25,000 shares of the firm’s stock in a transaction dated Friday, July 10th. The shares were sold at an average price of $401.33, for a total value of $10,033,250.00. Following the completion of the sale, the insider directly owned 194,989 shares in the company, valued at $78,254,935.37. This trade represents a 11.36% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 61,644 shares of company stock worth $24,016,214. 1.90% of the stock is currently owned by company insiders.

Broadcom Stock Performance Shares of Broadcom stock opened at $370.32 on Thursday. The company has a 50 day moving average of $395.11 and a 200-day moving average of $367.66. Broadcom Inc. has a 1-year low of $281.61 and a 1-year high of $495.00. The company has a current ratio of 2.24, a quick ratio of 2.01 and a debt-to-equity ratio of 0.71. The company has a market cap of $1.76 trillion, a PE ratio of 61.72, a price-to-earnings-growth ratio of 0.73 and a beta of 1.45.

Broadcom (NASDAQ:AVGO – Get Free Report) last announced its quarterly earnings data on Wednesday, June 3rd. The semiconductor manufacturer reported $2.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.40 by $0.04. Broadcom had a net margin of 38.85% and a return on equity of 41.61%. The business had revenue of $22.19 billion for the quarter, compared to analysts’ expectations of $22.13 billion. During the same period last year, the firm posted $1.58 earnings per share. The firm’s quarterly revenue was up 47.9% compared to the same quarter last year. As a group, equities research analysts forecast that Broadcom Inc. will post 10.24 earnings per share for the current fiscal year.

Broadcom Announces Dividend The firm also recently announced a quarterly dividend, which was paid on Tuesday, June 30th. Shareholders of record on Monday, June 22nd were issued a $0.65 dividend. This represents a $2.60 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date of this dividend was Monday, June 22nd. Broadcom’s dividend payout ratio (DPR) is currently 43.33%.

Analysts Set New Price Targets AVGO has been the subject of a number of recent research reports. Wall Street Zen downgraded shares of Broadcom from a “strong-buy” rating to a “buy” rating in a report on Saturday, July 18th. TD Cowen reiterated a “buy” rating and issued a $500.00 price target on shares of Broadcom in a research report on Thursday, June 4th. DA Davidson lifted their price target on shares of Broadcom from $375.00 to $400.00 and gave the company a “neutral” rating in a research report on Thursday, June 4th. Benchmark increased their price target on Broadcom from $485.00 to $545.00 and gave the stock a “buy” rating in a research report on Thursday, June 4th. Finally, KeyCorp reissued an “overweight” rating and set a $575.00 price target (up from $500.00) on shares of Broadcom in a research report on Thursday, June 4th. Twenty-eight analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $493.24.

Read Our Latest Report on AVGO

Key Broadcom News Here are the key news stories impacting Broadcom this week:

Positive Sentiment: Broadcom reportedly signed a five-year, $200 billion agreement with Samsung covering memory chips, including high-bandwidth memory (HBM), and potentially advanced packaging. The deal could help solve a key constraint for Broadcom’s AI accelerators by securing critical memory supply and supporting long-term growth. Broadcom Just Signed a $200 Billion AI Agreement Positive Sentiment: Analysts and investors remain optimistic that Broadcom’s custom AI-chip business and relationships with hyperscale cloud providers can continue benefiting from infrastructure spending. Some valuation analysis indicates AVGO may be below estimated fair value based on discounted cash flow and earnings multiples despite its strong long-term appreciation. Is Broadcom Stock Below Fair Value After Its AI Deals? Neutral Sentiment: The Samsung agreement highlights both the scale of AI demand and the industry’s rising costs. While guaranteed memory access may support revenue, the size of the commitment could pressure margins, capital requirements, and returns if AI demand or customer orders weaken. Broadcom’s $200 Billion Samsung Deal Negative Sentiment: Chip stocks have continued to pull back amid fears that AI-related valuations and capital spending expectations have become excessive, creating a broader headwind for AVGO. Chip Stocks Extend Pullback Amid AI Bubble Fears Negative Sentiment: One analyst raised concerns about AI “backstop” arrangements involving Broadcom and Nvidia, warning that these structures could leave the companies with additional liabilities if customers do not meet expected commitments. AI Backstop Concerns Broadcom Company Profile (Free Report)

Broadcom Inc (NASDAQ: AVGO) is a global technology company that designs, develops and supplies semiconductor and infrastructure software solutions for a broad range of markets. The company’s semiconductor business provides components and systems for wired and wireless communications, enterprise and cloud storage, networking and broadband access, serving original equipment manufacturers, cloud service providers, telecommunications carriers and industrial customers worldwide. Broadcom is headquartered in Irvine, California, and operates globally with research, development and sales organizations across North America, Europe and Asia.

On the semiconductor side, Broadcom’s portfolio includes system-on-chip (SoC) and application-specific integrated circuit (ASIC) solutions, radio-frequency and connectivity components, Ethernet switching and PHY devices, storage adapters and controllers, optical transceivers and other networking silicon.

Further Reading Five stocks we like better than Broadcom Why SK hynix Could Be the Best AI Chip Stock to Buy Now Seagate Technology Stock Surges as Earnings Beat Silences AI Doubters Alphabet Is Down 18% From Its High After a Stellar Quarter—Overdone, or More Downside Ahead? Why Bloom Energy May Be the Most Important AI Infrastructure Stock

Receive News & Ratings for Broadcom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Broadcom and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEArkadios Wealth Advisors Has $44.84 Million Holdings in Broadcom Inc. $AVGO

NEXT HEADLINE »Targa Resources (TRGP) to Release Quarterly Earnings on Thursday